<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79957</article-id><article-id pub-id-type="doi">10.7554/eLife.79957</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Dendritic cell Piezo1 directs the differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cells in cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-279411"><name><surname>Wang</surname><given-names>Yuexin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-279412"><name><surname>Yang</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-279413"><name><surname>Jia</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-279414"><name><surname>Wang</surname><given-names>Yufei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-279415"><name><surname>Yang</surname><given-names>Qiuli</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279416"><name><surname>Dong</surname><given-names>Yingjie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-289691"><name><surname>Hou</surname><given-names>Yueru</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-289690"><name><surname>Cao</surname><given-names>Yejin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-289689"><name><surname>Dong</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-72726"><name><surname>Bi</surname><given-names>Yujing</given-names></name><email>byj7801@sina.com</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-179114"><name><surname>Liu</surname><given-names>Guangwei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6008-2891</contrib-id><email>liugw@bnu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/022k4wk35</institution-id><institution>Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, College of Life Sciences, Beijing Normal University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013q1eq08</institution-id><institution>Department of Immunology, School of Basic Medical Sciences, Fudan University</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Smith</surname><given-names>Kellie N</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>The Johns Hopkins University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>Institute of Industrial Science, The University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>22</day><month>08</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e79957</elocation-id><history><date date-type="received" iso-8601-date="2022-05-03"><day>03</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-08-20"><day>20</day><month>08</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-05-18"><day>18</day><month>05</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.05.17.492270"/></event></pub-history><permissions><copyright-statement>© 2022, Wang, Yang, Jia et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Wang, Yang, Jia et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79957-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-79957-figures-v2.pdf"/><abstract><p>Dendritic cells (DCs) play an important role in anti-tumor immunity by inducing T cell differentiation. Herein, we found that the DC mechanical sensor Piezo1 stimulated by mechanical stiffness or inflammatory signals directs the reciprocal differentiation of T<sub>H</sub>1 and regulatory T (T<sub>reg</sub>) cells in cancer. Genetic deletion of Piezo1 in DCs inhibited the generation of T<sub>H</sub>1 cells while driving the development of T<sub>reg</sub> cells in promoting cancer growth in mice. Mechanistically, Piezo1-deficient DCs regulated the secretion of the polarizing cytokines TGFβ1 and IL-12, leading to increased TGFβR2-p-Smad3 activity and decreased IL-12Rβ2-p-STAT4 activity while inducing the reciprocal differentiation of T<sub>reg</sub> and T<sub>H</sub>1 cells. In addition, Piezo1 integrated the SIRT1-hypoxia-inducible factor-1 alpha (HIF1α)-dependent metabolic pathway and calcium-calcineurin-NFAT signaling pathway to orchestrate reciprocal T<sub>H</sub>1 and T<sub>reg</sub> lineage commitment through DC-derived IL-12 and TGFβ1. Our studies provide critical insight for understanding the role of the DC-based mechanical regulation of immunopathology in directing T cell lineage commitment in tumor microenvironments.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>dendritic cell</kwd><kwd>Piezo1</kwd><kwd>T cell differentiation</kwd><kwd>cancer</kwd><kwd>tumor microenvironment</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>National Natural Science Foundation for Key Programme of China</institution></institution-wrap></funding-source><award-id>31730024</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Guangwei</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>National Natural Science Foundation for General Program of China</institution></institution-wrap></funding-source><award-id>32170911</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Guangwei</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005089</institution-id><institution>Beijing Municipal Natural Science Foundation</institution></institution-wrap></funding-source><award-id>5202013</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Guangwei</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>National Natural Science Foundation for General Program of China</institution></institution-wrap></funding-source><award-id>31970863</award-id><principal-award-recipient><name><surname>Bi</surname><given-names>Yujing</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Detailed in vivo and in vitro experimental data in mice and human cell experimental data provide critical insight for understanding the role of the DC-based mechanical regulation of immunopathology in directing T cell lineage commitment in tumor microenvironments.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>CD4<sup>+</sup> T helper cells play a central role in cancer by differentiating into different T cell subsets including T<sub>H</sub>1 cells, T<sub>H</sub>2 cells, T<sub>H</sub>9 cells, T<sub>H</sub>17 cells, and regulatory T (T<sub>reg</sub>) cells, in specific cytokine environments (<xref ref-type="bibr" rid="bib54">Zhu et al., 2010</xref>; <xref ref-type="bibr" rid="bib1">Adorini, 2003</xref>). Foreign antigens and all kinds of innate stimuli are often presented by antigen-presenting cells (APCs) to further direct the development and differentiation of different subsets of CD4<sup>+</sup> T cells in tumor (<xref ref-type="bibr" rid="bib41">Steinman et al., 2003</xref>; <xref ref-type="bibr" rid="bib27">Marin et al., 2019</xref>). Inflammatory stimuli, such as bacterial lipopolysaccharide (LPS), cytokine, or other innate stimuli, such as oxygen, nutrient availability, and even force and pressure, can alter the immune responses. In particular, the tumor microenvironment often integrates different innate physiological or pathological stimuli to develop a complex stimulation microenvironment (<xref ref-type="bibr" rid="bib40">Solis et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">Geng et al., 2021</xref>). As professional APCs, dendritic cells (DCs) respond to various exogenous and endogenous stimuli mainly through three key signal pathways, including costimulatory molecule expression, T cell receptor (TCR) signaling, and cytokine production, bridging innate and adaptive immunity, and regulating the differentiation of different T cell subsets (<xref ref-type="bibr" rid="bib54">Zhu et al., 2010</xref>; <xref ref-type="bibr" rid="bib31">Murphy and Stockinger, 2010</xref>; <xref ref-type="bibr" rid="bib52">Zhou et al., 2008</xref>; <xref ref-type="bibr" rid="bib6">Chi, 2012</xref>; <xref ref-type="bibr" rid="bib29">McKinstry et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Li and Flavell, 2008</xref>; <xref ref-type="bibr" rid="bib43">Stockinger et al., 2007</xref>; <xref ref-type="bibr" rid="bib53">Zhu and Paul, 2010</xref>). DC-derived cytokines and chemokines exert proinflammatory or anti-inflammatory effects and are involved in the shaping of distinct T cell subset lineage programs to determine the prognosis of cancer patients. But, how the differentiation of CD4<sup>+</sup> T cells is modulated and regulated by innate immune signaling pathways in DCs in the tumor microenvironment remains unclear.</p><p>Piezo1 was originally identified as a mechanically activated non-selective cation ion channel with significant permeability to calcium ions, is evolutionary conserved and is involved in the proliferation and development of various types of cells in the context of various types of mechanical or innate stimuli. It has been reported that innate inflammatory stimulation or mechanical changes, such as changes in stiffness, can activate Piezo1 and trigger an inflammatory response (<xref ref-type="bibr" rid="bib10">Geng et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Yang et al., 2008</xref>). Piezo1 exerts significant regulatory effects on many kinds of immune cell functions including macrophages, DCs, and T cells in inflammation and cancer (<xref ref-type="bibr" rid="bib40">Solis et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">Geng et al., 2021</xref>; <xref ref-type="bibr" rid="bib3">Aykut et al., 2020</xref>; <xref ref-type="bibr" rid="bib2">Atcha et al., 2021</xref>; <xref ref-type="bibr" rid="bib4">Chakraborty et al., 2021</xref>; <xref ref-type="bibr" rid="bib15">Jairaman et al., 2021</xref>). However, it is still unclear whether Piezo1-targeted DCs affect the differentiation of different subsets of T cells in cancer.</p><p>Herein, we found that the DC mechanical sensor Piezo1 stimulated by mechanical stiffness or inflammatory signals directs the reciprocal differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cells in inhibiting tumor growth.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Inflammatory and stiffness stimuli alter Piezo1 expressions by DCs</title><p>As reported (<xref ref-type="bibr" rid="bib4">Chakraborty et al., 2021</xref>; <xref ref-type="bibr" rid="bib25">Liu et al., 2018</xref>), environmental stiffness can alter the secretion of inflammatory factors by DCs and the mechanical force receptor Piezo1 may be involved in this regulation. We first examined the effect of environmental stiffness on the expression of Piezo1 in DCs. We used a cell culture system consisting of a polydimethylsiloxane (PDMS) hydrogel-coated plate, as described (<xref ref-type="bibr" rid="bib50">Yang et al., 2008</xref>; <xref ref-type="bibr" rid="bib25">Liu et al., 2018</xref>). The mechanical properties of the PDMS hydrogel can be changed by adjusting the matrix/curing agent ratio, and this ratio can be precisely adjusted to simulate physiological tension. Consistent with previous reports (<xref ref-type="bibr" rid="bib50">Yang et al., 2008</xref>; <xref ref-type="bibr" rid="bib25">Liu et al., 2018</xref>), we used 2 kPa to mimic lymphoid tissue under physiological conditions and 50 kPa to mimic lymphoid tissue under inflammatory conditions. Sorted splenic DCs cultured on a stiff hydrogel (E=50 kPa) or plastic plates exhibited significantly enhanced expression of the proinflammatory cytokine IL-12 and diminished expression of the anti-inflammatory cytokine TGFβ1 compared with DCs cultured on a pliant hydrogel (E=2 kPa; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). This suggests that substrate stiffness could regulate inflammatory cytokine secretion by DCs. Moreover, the expression of the mechanical force receptor Piezo1 was significantly upregulated in 50 kPa-conditioned hydrogels compared with 2 kPa-conditioned hydrogels, similar to that in DCs stimulated with the inflammatory stimulus LPS (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Although 50 kPa-conditioned hydrogels significantly caused more IL-12 and less TGFβ1 compared with 2 kPa, mechanical force receptor Piezo1-deficient DC cells significant rescue them to normal level (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). These data suggested that mechanical force receptor Piezo1 mediated the inflammatory cytokine production induced by substrate stiffness in DCs.</p></sec><sec id="s2-2"><title>DC-specific Piezo1-deficient mice exhibited altered T cell differentiation</title><p>To investigate the regulatory effect of Piezo1 expressed by DCs on T cell function, we generated DC-specific Piezo1 conditional knockout (<italic>Piezo1</italic><sup>-/-</sup>) mice with <italic>Piezo1</italic><sup>flox/flox</sup> and <italic>Cd11c-cre. Piezo1</italic><sup>-/-</sup> mice showed no obvious abnormalities after birth. However, after 40 weeks of age, these mice showed lower weight loss and less T cell activation in mesenteric lymph nodes (MLNs), Peyer’s patches (PPs), intraepithelial lymphocytes (IELs), and lamina propria lymphocytes (LPLs) than WT mice (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Importantly, Piezo1 deficiency in DCs results in fewer IFNγ<sup>+</sup> T<sub>H</sub>1 cells and more Foxp3<sup>+</sup> T<sub>reg</sub> cells but does not affect the numbers of T<sub>H</sub>2 or T<sub>H</sub>17 cells (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Thus, we conclude that DC-specific Piezo1 deficiency alters the differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cells in aged mice, which might be related to clinical manifestations.</p></sec><sec id="s2-3"><title>DC-specific Piezo1 regulates T cell differentiation in promoting tumor growth</title><p>Next, we studied the effect of DC-specific Piezo1 deletion on T cell differentiation in MC38 mouse colon cancer. We observed changes in tumor growth in <italic>Piezo1</italic><sup>-/-</sup> and WT mice. The rate of tumor growth was signiﬁcantly faster and greater in <italic>Piezo1</italic><sup>-/-</sup> than in WT mice (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). <italic>Piezo1</italic><sup>-/-</sup> mice had more Foxp3<sup>+</sup> T<sub>reg</sub> cells, fewer IFNγ<sup>+</sup> T<sub>H</sub>1 cells, and normal numbers of T<sub>H</sub>2, T<sub>H</sub>17, CD8<sup>+</sup>T cell, and IFNγ<sup>+</sup>CD8<sup>+</sup>T cells in tumor tissue compared with WT control (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A-B</xref>). Furthermore, we isolated T cells from draining lymph nodes (dLNs) of tumor-bearing mice at day 20, 30, and 40 and observed dynamic T cell differentiation. Both <italic>Tbx21</italic> and <italic>Ifng</italic> levels were downregulated rapidly, <italic>Foxp3</italic> expression in T cells was upregulated gradually, and <italic>Il4</italic>, <italic>Il10</italic>, <italic>Il17a</italic>, and <italic>Gata3</italic>, <italic>Rorgt</italic> expressions did not change in <italic>Piezo1</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4C</xref>). Similar tumor growth and T cell differentiation were also observed in B16.F10 melanoma tumor (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). Thus, these data suggest that DC-specific Piezo1 deficiency probably directs T<sub>reg</sub> and T<sub>H</sub>1 cell differentiation to promote the tumor growth in the context of tumor microenvironment.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Dendritic cell (DC)-specific Piezo1 regulates T cell differentiation in cancer.</title><p>(<bold>A</bold>) MC38 tumor cells were implanted subcutaneously in WT and <italic>Piezo1</italic><sup>-/-</sup> mice (n=10) and tumor size was measured every 5 days for 40 days. (<bold>B</bold>) Intracellular staining of IFNγ, IL-4, IL-17A, and Foxp3 expression by CD4<sup>+</sup> T cells sorting from the tumor of WT and <italic>Piezo1</italic><sup>-/-</sup> tumor-bearing mice at day 40. (<bold>C</bold>) mRNA expression of the indicated genes by CD4<sup>+</sup> T cells isolated from the draining lymph nodes (dLNs) of tumor from WT and <italic>Piezo1</italic><sup>-/-</sup> tumor-bearing mice on the indicated days (the levels in WT mice at day 20 were set to 1). (<bold>D</bold>) MC38 OVA tumor cells were implanted subcutaneously in WT and <italic>Piezo1</italic><sup>-/-</sup> mice (n=10) and at day 20, the CD45.1<sup>+</sup> donor CFSE<sup>+</sup>OTII CD4<sup>+</sup>T cells were transferred into WT and <italic>Piezo1</italic><sup>-/-</sup> tumor-bearing mice for 10 days. The CD45.1<sup>+</sup> CFSE<sup>+</sup> donor T cells from tumors were analyzed and the intracellular staining of IFNγ, IL-4, IL-17A, and Foxp3 expression among CFSE<sup>low</sup> donor T cells. The data are representative of three to four independent experiments (mean ± s.d.; n=4). **p&lt;0.01 and ***p&lt;0.001, compared with the indicated groups.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Tumor size in WT and <italic>Piezo1</italic><sup>-/-</sup> tumor-bearing mice.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79957-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Piezo1 expressions of dendritic cells (DCs) following innate stimuli.</title><p><italic>Il12b</italic> and <italic>Tgfb1</italic> mRNA (<bold>A and C</bold>) and <italic>Piezo1</italic> mRNA (<bold>B</bold>) expression of splenic DCs from C57BL/6 or/and <italic>Piezo1</italic><sup>-/-</sup> mice with the indicated treatment (lipopolysaccharide [LPS], 10 ng/ml or conditioned with 2 or 50 kPa hydrogels plate). Levels in the vehicle group were set to 1. Data are representative of three to four independent experiments (mean ± s.d.; n=3–4). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Dendritic cell (DC)-specific Piezo1 deficiency reduced T cell activities in aged mice.</title><p>(<bold>A</bold>) Body weights of WT and <italic>Piezo1</italic><sup>-/-</sup> mice are shown (n=20). (<bold>B–C</bold>) Piezo1 deficiency in DCs resulted in less CD44<sup>high</sup>CD62<sup>Low</sup> cells in the CD4<sup>+</sup> T cell population than WT DCs. A typical figure shown in B and data summarized in C. The data are representative of three independent experiments (mean ± s.d.; n=4–20). *p&lt;0.05 and ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Dendritic cell (DC)-specific Piezo1 deficiency alters T cell differentiation in the aged mice.</title><p>Intracellular IFNγ, IL-4, IL-17A, and Foxp3 expression by CD4<sup>+</sup> T cells from the mesenteric lymph node (MLN), Peyer’s patche (PP), intraepithelial lymphocyte (IEL), and lamina propria lymphocyte (LPL) in WT and <italic>Piezo1</italic><sup>-/-</sup> mice. A representative figure shown (<bold>A</bold>), and the percentage of positive cells summarized (<bold>B</bold>). The data are representative of three independent experiments (mean ± s.d.; n=4–5). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Dendritic cell (DC)-specific Piezo1 regulates T cell differentiation in cancer.</title><p>MC38 tumor cells were implanted subcutaneously in WT and <italic>Piezo1</italic><sup>-/-</sup> mice (n=10). (<bold>A</bold>) CD8<sup>+</sup>T cell number in tumor of WT and <italic>Piezo1</italic><sup>-/-</sup> tumor-bearing mice at day 40. (<bold>B</bold>) Intracellular staining of IFNγ expression of CD8<sup>+</sup> T cells from the tumor of WT and <italic>Piezo1</italic><sup>-/-</sup> tumor-bearing mice at day 40. The representative data from flow cytometry analysis shown (left), and statistical results summarized (right). (<bold>C</bold>) mRNA expression of the indicated genes by CD4<sup>+</sup> T cells isolated from the draining lymph nodes (dLNs) of tumor from WT and <italic>Piezo1</italic><sup>-/-</sup> tumor-bearing mice on the indicated days (the levels in WT mice at day 20 were set to 1). The data are representative of three independent experiments (mean ± s.d.; n=4). n.s., not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig1-figsupp4-v2.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Dendritic cell (DC)-specific Piezo1 regulates T cell differentiation in cancer.</title><p>(<bold>A</bold>) B16.F10 tumor cells were implanted subcutaneously in WT and <italic>Piezo1</italic><sup>-/-</sup> mice (n=10) and tumor size was measured every 5 days for 30 days. (<bold>B</bold>) Intracellular staining of IFNγ, IL-4, IL-17A, and Foxp3 expression of CD4<sup>+</sup> T cells sorted from the tumor of WT and <italic>Piezo1</italic><sup>-/-</sup> tumor-bearing mice at day 30. The representative data from flow cytometry analysis shown (left), and statistical results summarized (right). The data are representative of three to four independent experiments (mean ± s.d.; n=4). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig1-figsupp5-v2.tif"/></fig></fig-group><p>Further, we observed the antigen-specific responses of T cells in tumor-bearing mice during tumor growth. MC38-OVA tumor cells were implanted subcutaneously in WT and <italic>Piezo1</italic><sup>-/-</sup> mice. And at day 20 after tumor cell implantation, naïve CD45.1<sup>+</sup> OTII T cells were isolated from OTII-TCR transgenic mice, labeled with CFSE and transferred into WT and <italic>Piezo1</italic><sup>-/-</sup>-bearing tumor recipient mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). After 10 days of adoptive transfer of OTII T cells to recipient tumor-bearing mice, the intracellular staining of the CD45.1<sup>+</sup> CFSE<sup>+</sup> donor T cells from tumors in recipient WT and <italic>Piezo1</italic><sup>-/-</sup> mice analyzed showed that the percentage of CFSE<sup>+</sup> T cells is similar between WT and <italic>Piezo1</italic><sup>-/-</sup>-bearing tumor mice. However, there are more Foxp3<sup>+</sup>T<sub>reg</sub> cells and less IFNγ<sup>+</sup>T<sub>H</sub>1 cells, but similar T<sub>H</sub>2 and T<sub>H</sub>17 cells in <italic>Piezo1</italic><sup>-/-</sup> compared with WT bearing-tumor mice (<xref ref-type="fig" rid="fig1">Figure 1D–E</xref>). These data suggest that Piezo1 in DCs regulates the T<sub>H</sub>1 and T<sub>reg</sub> differentiation in tumor microenvironment with the antigen-specific manner.</p></sec><sec id="s2-4"><title>DC-specific Piezo1 expression instructs antigen-specific T<sub>H</sub>1 and T<sub>reg</sub> cell differentiation</title><p>Next, we conducted an adoptive transfer experiment to investigate the T cell response induced by DC Piezo1. Naïve T cells (CD45.2<sup>+</sup>CD4<sup>+</sup>TCR<sup>+</sup>CD44<sup>low</sup>CD62L<sup>high</sup>) from C57BL/6 mice were transferred into CD45.1<sup>+</sup>C57BL/6 recipient mice, and then, the recipient mice were immunized with WT and <italic>Piezo1</italic><sup>-/-</sup> splenic DCs and LPS. The donor cells were analyzed on day 10 after immunization. T cell proliferation was comparable between the WT and <italic>Piezo1</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). However, the recipient mice immunized with <italic>Piezo1</italic><sup>-/-</sup> splenic DCs exhibited more Foxp3<sup>+</sup>CD4<sup>+</sup> T cells and less IFNγ<sup>+</sup>CD4<sup>+</sup> T cells. Both the WT and <italic>Piezo1</italic><sup>-/-</sup> mice showed similar levels of IL-4 and IL-17 expression among donor CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig2">Figure 2B–C</xref>). Furthermore, the antigen-specific responses of donor T cells were investigated. Naïve OTII T cells were isolated and transferred into CD45.1<sup>+</sup> C57BL/6 recipient mice which immunized with WT and <italic>Piezo1</italic><sup>-/-</sup> DCs and antigen. Although WT and <italic>Piezo1</italic><sup>-/-</sup> showed similar T cell proliferation (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), donor cells immunized with <italic>Piezo1</italic><sup>-/-</sup> DCs exhibited more Foxp3<sup>+</sup> cells, fewer IFNγ<sup>+</sup> cells, and similar numbers of IL-4<sup>+</sup>T<sub>H</sub>2 cells and IL-17A<sup>+</sup>T<sub>H</sub>17 cells (<xref ref-type="fig" rid="fig2">Figure 2E–F</xref>). Further, we examined DCs conditioned by 2 or 50 kPa hydrogel in adoptive transfer experiments. Splenic DCs were isolated from WT and <italic>Piezo1</italic><sup>-/-</sup> mice and plated on 2 or 50 kPa hydrogels. Naïve T cells or OTII T cells were isolated and transferred into CD45.1<sup>+</sup> recipient mice, the recipient mice were immunized with 2 or 50 kPa hydrogel-conditioned DCs with or without antigen. Donor T cells from mice immunized with <italic>Piezo1</italic><sup>-/-</sup> DCs conditioned with 50 kPa, but not 2 kPa, hydrogels included more Foxp3<sup>+</sup> T<sub>reg</sub> cells and less IFNγ<sup>+</sup> T<sub>H</sub>1 cells (<xref ref-type="fig" rid="fig2">Figure 2G–H</xref>). Altogether, these data suggest that the mechanical sensor Piezo1 in DCs stimulated by innate inflammatory or stiffness stimuli directs the reciprocal differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cells.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Dendritic cell (DC)-specific Piezo1 expression directs the differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cells in vivo.</title><p>(<bold>A–C</bold>) Naïve CD45.2<sup>+</sup> T cells were transferred into CD45.1<sup>+</sup> C57BL/6 WT mice, and the mice were immunized with WT and <italic>Piezo1</italic><sup>-/-</sup> splenic DCs and lipopolysaccharide (LPS). DLN cells were analyzed at day 7 after immunization. (<bold>A</bold>) Donor CD45.2<sup>+</sup> T cell proliferation after stimulation with anti-CD3 (2 µg/ml) and anti-CD28 (2 μg/ml) antibodies. (<bold>B–C</bold>) Intracellular staining of IFNγ, IL-4, IL-17A, and Foxp3 expression in donor-derived (CD45.2<sup>+</sup>) CD4<sup>+</sup> T cells after PMA and ionomycin stimulation. A representative figure shown in B, and the data summarized in C. (<bold>D–F</bold>) Naïve OTII T cells were transferred into CD45.1<sup>+</sup> C57BL/6 WT mice, and the mice were immunized with WT and <italic>Piezo1</italic><sup>-/-</sup> splenic DCs and OVA+CFA. DLN cells were analyzed at day 7 after immunization. (<bold>D</bold>) Donor CD45.2<sup>+</sup> T cell proliferation after stimulation with OVA. (<bold>E–F</bold>) Intracellular staining of IFNγ, IL-4, IL-17A, and Foxp3 in donor-derived (CD45.2<sup>+</sup>) CD4<sup>+</sup> T cells after OVA stimulation. A representative figure shown in E, and the data summarized in F. (<bold>G–H</bold>) Splenic DCs isolated from WT and <italic>Piezo1</italic><sup>-/-</sup> mice were plated on 2 and 50 kPa hydrogels and incubated for 24 hr. (<bold>G</bold>) Naïve T cells were transferred into CD45.1<sup>+</sup> C57BL/6 WT mice, and the mice were immunized with 2 and 50 kPa hydrogel-conditioned DCs. DLN cells were analyzed at day 7 after immunization. Intracellular staining of IFNγ, IL-4, and IL-17A in donor-derived (CD45.2<sup>+</sup>) CD4<sup>+</sup> T cells after PMA and ionomycin stimulationand data summarized. (<bold>H</bold>) Naïve OTII T cells were transferred into CD45.1<sup>+</sup> C57BL/6 WT mice, and the mice were immunized with 2 or 50 kPa hydrogel-conditioned DCs and OVA+CFA. DLN cells were analyzed at day 7 after immunization. Intracellular staining of IFNγ, IL-4, and IL-17A in donor-derived (CD45.2<sup>+</sup>) CD4<sup>+</sup> T cells after OVA stimulation and data summarized. The data are representative of three to four independent experiments (mean ± s.d.; n=3–4). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig2-v2.tif"/></fig></sec><sec id="s2-5"><title>Piezo1 is required for DC-dependent T cell differentiation</title><p>Next, we investigated the effects of Piezo1 expression by DCs on T cell subset differentiation in an in vitro system. Polyclonal T cells or antigen-specific OTII T cells cocultured with <italic>Piezo1</italic><sup>-/-</sup> DCs in the absence or presence of antigen induced more Foxp3<sup>+</sup>T<sub>reg</sub> cell and less IFNγ<sup>+</sup> T<sub>H</sub>1 cell, even with a variety of <italic>Piezo1</italic><sup>-/-</sup> DCs including splenic CD11b<sup>+</sup> DC or CD8α<sup>+</sup> DCs, than WT control DCs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Moreover, <italic>Tbx21</italic> and <italic>Ifng</italic> expression was significantly downregulated and <italic>Foxp3</italic> expression was significantly upregulated in T cells cocultured with <italic>Piezo1</italic><sup>-/-</sup> DCs. However, <italic>Il4</italic>, <italic>Il10</italic>, <italic>Il17a</italic> and <italic>Gata3</italic>, <italic>Rorgt</italic> expressions were similar in T cells cocultured with <italic>Piezo1</italic><sup>-/-</sup> DCs or WT DCs (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). These data suggest that Piezo1 deficiency in different kinds of DCs including CD11b<sup>+</sup> DC and CD8α<sup>+</sup> DC subsets regulates the reciprocal differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cells in an antigen-specific manner. Coculture of antigen-specific OTII T cells with <italic>Piezo1</italic><sup>∆DC</sup> splenic CD11b<sup>+</sup> DCs conditioned by 2 or 50 kPa hydrogels in the presence of antigen induced a higher expression of Foxp3 and a lower expression of IFNγ (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B-C</xref>). Together, Piezo1 signals are required for reciprocal T<sub>H</sub>1 and T<sub>reg</sub> cell differentiation directed by DCs in an antigen-specific manner.</p></sec><sec id="s2-6"><title>DC Piezo1 regulates T cell differentiation through IL-12 and TGFβ1</title><p>APCs regulate T cell differentiation by changing costimulatory molecule expression, TCR signaling, and polarizing cytokine production (<xref ref-type="bibr" rid="bib41">Steinman et al., 2003</xref>). Piezo1 deficient does not alter the cell homeostasis level (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A</xref>), the expression of MHC, the costimulatory molecules CD80, CD86, CD54, PDL1, PDL2, and CCR7 expressions in DCs (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3B-C</xref>). And, the phagocytosis activities of DC to IgG-coated beads is also comparable between WT and <italic>Piezo1</italic><sup>-/-</sup> DCs (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3D</xref>). Next, we also detected changes in cytokines secreted by splenic DCs, especially polarizing cytokines important for inducing T<sub>H</sub>1 and T<sub>reg</sub> cell differentiation. First, we isolated the DC from MLNs at 40 weeks of age mice and found that <italic>Piezo1</italic><sup>-/-</sup> DCs have less IL-12 (p70) and more TGFβ1 expression (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4A</xref>). These suggest the intestinal environment receives continuous antigen stimulation from microorganisms or food, which may lead to changes in intestinal tension caused by intestinal movements such as food digestion and absorption or inflammatory stimuli, and target the Piezo1 signal of DCs to trigger the differentiation of different subsets of T cells in the aged mice. Next, we found that <italic>Piezo1</italic><sup>-/-</sup> caused DCs significantly higher TGFβ1 production and lower IL-12 (p40), IL-12 (p70), but not IL-23 production in the presence of LPS (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4B-C</xref>) or 50 kPa, but not 2 kPa, hydrogels (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). These results together suggest that the polarizing cytokines TGFβ1 and IL-12 are probably involved in regulating T cell subset differentiation induced by Piezo1 in DCs stimulating by inflammatory stimuli or stiffness signals.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Piezo1 regulates IL-12 and TGFβ1 production by dendritic cells (DCs) to direct T<sub>H</sub>1 and T<sub>reg</sub> cell differentiation.</title><p>(<bold>A–B</bold>) Intracellular staining of IL-12p40 and TGFβ1 expression in WT and <italic>Piezo1</italic><sup>-/-</sup> splenic DCs after 5 hr of treatment with lipopolysaccharide (LPS) (A; 10 ng/ml) or culture on 2 and 50 kPa hydrogels (<bold>B</bold>). A representative figure shown on the left, and the data summarized on the right. (<bold>C</bold>) Intracellular staining of IFNγ and Foxp3 in T cells cocultured with WT and <italic>Piezo1</italic><sup>-/-</sup> splenic DCs in the presence of the indicated treatments (IL-12, Peprotech, 10 μg/ml or anti-TGFβ1, R&amp;D Systems, 20 μg/ml) for 5 days. A representative figure shown on the left, and the data summarized on the right. (<bold>D</bold>) Intracellular staining of IFNγ (upper panel) and Foxp3 (lower panel) in T cells cocultured with WT and <italic>Piezo1</italic><sup>∆DC</sup> splenic DCs conditioned with 50 kPa hydrogel and the indicated treatments for 5 days and data summarized. The data are representative of three independent experiments (mean ± s.d.; n=3–5). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Dendritic cell (DC)-specific Piezo1 expression directs T<sub>H</sub>1 and T<sub>reg</sub> differentiation in vitro.</title><p>(<bold>A–B</bold>) C57BL/6 naïve CD4<sup>+</sup> T cells were cocultured with lipopolysaccharide (LPS)-pulsed splenic CD11b<sup>+</sup> DCs (<bold>A</bold>) or CD8<sup>+</sup> DCs (<bold>B</bold>) from WT and <italic>Piezo1</italic><sup>-/-</sup> mice for 5 days. Intracellular staining of IFNγ and Foxp3 in T cells. A representative figure shown on the left, and the data summarized on the right. (<bold>C–D</bold>) Naïve CD4<sup>+</sup> T cells from OTII mice were cocultured with LPS-pulsed splenic CD11b<sup>+</sup> DCs (<bold>C</bold>) or CD8<sup>+</sup> DCs (<bold>D</bold>) from WT and <italic>Piezo1</italic><sup>-/-</sup> mice for 5 days. Intracellular staining of IFNγ and Foxp3 in T cells. A representative figure shown on the left, and the data summarized on the right. The data are representative of three independent experiments (mean ± s.d.; n=3–6). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Dendritic cell (DC)-specific Piezo1 expression directs T<sub>H</sub>1 and T<sub>reg</sub> differentiation in vitro.</title><p>(<bold>A</bold>) Naïve T cells from C57BL/6 mice were cocultured with splenic DCs from WT and <italic>Piezo1</italic><sup>-/-</sup> mice for 5 days in the presence of anti-CD3 (2 ng/ml) and lipopolysaccharide (LPS) (10 ng/ml). The relative mRNA expression of the indicated genes in T cells was determined with qPCR. The levels in the WT group and on day 0 were set to 1. (<bold>B</bold>) splenic CD11b<sup>+</sup> DCs isolated from WT and <italic>Piezo1</italic><sup>-/-</sup> mice were plated on 2 and 50 kPa hydrogels (1×10<sup>5</sup> cells/well) for 24 hs. Naïve CD4<sup>+</sup> T cells from OTII mice were cocultured with 2 and 50 kPa hydrogel-conditioned DCs in the presence of OVA (5 μg/ml) for 5 days. Intracellular staining of IFNγ, IL-4, IL-17A, and Foxp3 in T cells. (<bold>C</bold>) Naïve T cells from OTII mice were cocultured with 2 and 50 kPa hydrogel-conditioned splenic CD11b<sup>+</sup> DCs in the presence of OVA (5 μg/ml) for 5 days. The relative mRNA expression of the indicated genes in T cells was determined with qPCR. The levels in the WT group with 2 kPa were set to 1. The data are representative of three independent experiments (mean ± s.d.; n=4–6). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Piezo1 regulates dendritic cell (DC) homeostasis and function.</title><p>(<bold>A</bold>) 7-AAD and Annexin V staining in WT and <italic>Piezo1</italic><sup>-/-</sup> splenic DCs. The representative data from flow cytometry analysis shown (left), and data summarized (right). (<bold>B–C</bold>) Expression of indicated molecules in WT and <italic>Piezo1</italic><sup>-/-</sup> splenic DCs in the presence of lipopolysaccharide (LPS) (10 ng/ml) from flow cytometry analysis. (<bold>D</bold>) Phagocytosis of WT and <italic>Piezo1</italic><sup>-/-</sup> splenic DCs to IgG-coated beads in the presence of LPS (10 ng/ml). The representative data from flow cytometry shown (left), and data summarized (right). Data are representative of three independent experiments (mean ± s.d.; n=3). n.s., not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Piezo1 regulates dendritic cell (DC) cytokine production.</title><p>(<bold>A</bold>) mRNA expressions of <italic>Il12</italic> (p70) and <italic>Tgfb1</italic> expression in WT and <italic>Piezo1</italic><sup>-/-</sup> mesenteric lymph node (MLN) DCs. (<bold>B</bold>) mRNA expressions of <italic>Il12</italic> (p70), <italic>Il23,</italic> and <italic>Tgfb1</italic> expression in WT and <italic>Piezo1</italic><sup>-/-</sup> splenic DCs treated with lipopolysaccharide (LPS) (10 ng/ml) for 5 hr. (<bold>C</bold>) Production of IL-12p70 (left panel) and TGFβ1 (right panel) in culture supernatant in WT and <italic>Piezo1</italic><sup>-/-</sup> splenic DCs treated with LPS (10 ng/ml) for 5 hr. The data are representative of three independent experiments (mean ± s.d.; n=3). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig3-figsupp4-v2.tif"/></fig></fig-group><p>We selected a splenic DC-T coculture system to determine whether DC-specific Piezo1 expression regulates T cell subset differentiation through the polarizing cytokines TGFβ1 and IL-12. Although Piezo1 deficiency in DCs caused a significantly lower IFNγ<sup>+</sup> T<sub>H</sub>1 cell percentage, adding IL-12 to the coculture system almost completely recovered the proportion of <italic>Piezo1</italic><sup>-/-</sup> DCs during T<sub>H</sub>1 cell differentiation (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Even DCs conditioned by 50 kPa hydrogel treatment caused similar effects (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Consistently, blocking TGFβ1 signaling with an anti-TGFβ1 antibody in the coculture system almost completely recovered the effect of <italic>Piezo1</italic><sup>-/-</sup> splenic DCs on T<sub>reg</sub> cell differentiation. Similar effects could be observed when DCs were treated with LPS or 50 kPa hydrogels (<xref ref-type="fig" rid="fig3">Figure 3C–D</xref>). Thus, we could conclude that DC-specific Piezo1 expression regulates the reciprocal differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cells through the polarizing cytokines IL-12 and TGFβ1.</p></sec><sec id="s2-7"><title>DC-specific Piezo1 expression induces T cell differentiation through TGFβR2 and IL-12Rβ2</title><p>T cell differentiation-inducing cytokines often change the corresponding receptors on the surface of T cells and program the differentiation of T cell subsets (<xref ref-type="bibr" rid="bib54">Zhu et al., 2010</xref>; <xref ref-type="bibr" rid="bib24">Liu et al., 2010</xref>). We further determined the corresponding receptor expression on T cells. Piezo1 deficiency in splenic DCs significantly increased the expression of TGFβR2 and decreased the expression of IL-12Rβ2 but did not affect the expression of TGFβR1/3 or IL-12Rβ1 on T cells in a DC-T coculture system (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Interestingly, Piezo1-deficient DCs also exhibited significantly higher levels of phosphorylated Smad3 and lower levels of phosphorylated STAT4 than WT DCs (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). These data suggest that TGFβR2-p-Smad3 or IL-12Rβ2-p-STAT4 signaling is involved in the T<sub>reg</sub> and T<sub>H</sub>1 cell differentiation induced by DC-specific Piezo1 expression.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>TGFβR2-pSmad3 and IL-12Rβ2-pSTAT4 are required for the T cell differentiation induced by dendritic cell (DC)-specific Piezo1 expression.</title><p>(<bold>A</bold>) Expression of TGFβR2 and IL-12Rβ2 in T cells cocultured with WT or <italic>Piezo1</italic><sup>-/-</sup> splenic DCs for 5 days. A representative figure shown on the left, and the data summarized on the right. (<bold>B</bold>) Intracellular staining of p-Smad3 and p-STAT4 in T cells cocultured with WT or <italic>Piezo1</italic><sup>-/-</sup> splenic DCs for 5 days. A representative figure shown on the left, and the data summarized on the right. (<bold>C–D</bold>) Sorted naïve T cells were transfected with control, <italic>Tgfbr2</italic> short hairpin RNA (shRNA) vector, or <italic>Il12rb2</italic> shRNA vector and cocultured with WT or <italic>Piezo1</italic><sup>-/-</sup> DCs for 5 days. Intracellular staining of IFNγ (C; upper panel) and Foxp3 (C; lower panel) in T cells. A representative figure shown on the left, and the data summarized on the right. (<bold>D</bold>) Intracellular staining of p-Smad3 and p-STAT4 in T cells and data summarized. The data are representative of three independent experiments (mean ± s.d.; n=4). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Expressions of TGFβR1/2 and IL-12Rβ1 in T cells induced by <italic>Piezo1</italic><sup>-/-</sup> dendritic cells (DCs).</title><p>Expression of TGFβR1, TGFβR3 (<bold>A</bold>), and IL-12Rβ1 (<bold>B</bold>) in T cells cocultured with WT or <italic>Piezo1</italic><sup>-/-</sup> splenic DCs for 5 days. Data are representative of three independent experiments (mean ± s.d.; n=4).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Knockdown of <italic>Tgfbr2</italic> short hairpin RNA (shRNA) and <italic>Il12rb2</italic> shRNA in T cells.</title><p>Sorted CD4<sup>+</sup> T cells were transfected with control or <italic>Tgfbr2</italic> shRNA vector (<bold>A</bold>) or <italic>Il12rb2</italic> shRNA vector (<bold>B</bold>) and stimulated with WT or <italic>Piezo1</italic><sup>-/-</sup> splenic dendritic cells (DCs) for 5 days in the presence of lipopolysaccharide (LPS) (10 ng/ml). Expression of indicated mRNA (A or B) was determined with qPCR (levels of Ctrl siRNA were set to 1). Data are representative of three independent experiments (mean ± s.d.; n=3). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig4-figsupp2-v2.tif"/></fig></fig-group><p>To determine whether TGFβR2-pSmda3 and IL-12Rβ2-pSTAT4 are required for promoting the T cell differentiation induced by DC-specific Piezo1 expression, we knocked down IL-12Rβ2 and TGFβR2 expression in T cells with shRNA in a DC-T coculture system (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Although DC-specific Piezo1 deficiency resulted in significantly more Foxp3<sup>+</sup> T<sub>reg</sub> cells, higher phosphorylation of Smad3, and less IFNγ<sup>+</sup> T<sub>H</sub>1 cells, lower phosphorylation of STAT4, knockdown of TGFβR2 or IL-12Rβ2 expression significantly recovered these effects compared with the WT conditions (<xref ref-type="fig" rid="fig4">Figure 4C–D</xref>). These data suggest that TGFβR2-pSmda3 and IL-12Rβ2-pSTAT4 signaling in T cells are required for the T cell differentiation induced by DC Piezo1.</p></sec><sec id="s2-8"><title>Piezo1 regulates IL-12 and TGFβ1 production through the SIRT1-HIF1α-glycolysis pathway</title><p>How does Piezo1 regulate IL-12 and TGFβ1 production to direct T cell differentiation? To study the mechanisms underlying the effects of Piezo1, splenic DCs were stimulated by LPS, and we assessed the signaling downstream of LPS stimulation, including Erk, c-jun-NH2-kinase (JNK), p38MAPK, SIRT1, HIF1α, and glycolytic molecular signaling.</p><p>We investigated the role of glycolysis and oxidative phosphorylation (OXPHOS) signal activities in the functional regulation of DCs induced by Piezo1. LPS treatment led to an increase in the proton production rate (PPR), but splenic DCs treated with the Piezo1 agonist Yoda1 exhibited significantly enhanced PPR values and expression of glycolytic molecules but not oxygen consumption rates (OCRs) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Blocking glycolysis with 2-deoxy-D-glucose (2-DG), a prototypical inhibitor of glycolysis pathways, significantly recovered the IL-12 and TGFβ1 production in splenic DCs induced by Yoda1 treatment (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Furthermore, Piezo1 deficiency in DCs significantly decreased the PPR value and the expression of glycolytic molecules but not the OCR value (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A</xref>). Blocking glycolysis with 2-DG significantly recovered the productions of IL-12 and TGFβ1 in <italic>Piezo1</italic><sup>-/-</sup> DCs to normal level compared with WT DCs (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3B-C</xref>). These data altogether suggest that glycolysis activities are required for the polarizing cytokine production in DCs induced by Piezo1.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Piezo1 regulates TGFβ1 and IL-12 production through the SIRT1-HIF1α-glycolysis pathway.</title><p>(<bold>A–B</bold>) Sorted splenic dendritic cells (DCs) from WT or <italic>Piezo1</italic><sup>-/-</sup> mice were stimulated with lipopolysaccharide (LPS) (10 ng/ml; <bold>A</bold>) or with 2 or 50 kPa hydrogels (<bold>B</bold>) for 24 hr in the presence or absence of 2-deoxy-D-glucose (2-DG) (1 mmol/l). The proton production rate (PPR) was analyzed as a readout for glycolysis. (<bold>C</bold>) mRNA expression of glycolytic molecules in splenic DCs from WT or <italic>Piezo1</italic><sup>-/-</sup> mice treated with LPS (10 ng/ml) for 12 hr. The levels in the WT control group were set to 1. (<bold>D</bold>) Intracellular staining of p38, Erk, and JNK phosphorylation and SIRT1 and HIF1α expression in splenic DCs from WT or <italic>Piezo1</italic><sup>-/-</sup> mice. A representative figure shown in the upper panel, and the data summarized in the lower panel. (<bold>E</bold>) Splenic DCs from WT, <italic>Piezo1</italic><sup>-/-</sup> , <italic>Sirt1</italic><sup>-/-</sup>, and <italic>Piezo1</italic>/<italic>Sirt1</italic> double knockout (DKO; <italic>Piezo1</italic><sup>-/-</sup><italic>Sirt1</italic><sup>-/-</sup>) mice were stimulated with LPS (10 ng/ml). Intracellular staining of IL-12p40. A representative figure shown on the left, and the data summarized on the right. (<bold>F</bold>) Splenic DCs from WT or <italic>Hif1a</italic><sup>-/-</sup> mice were stimulated with LPS (10 ng/ml) in the presence or absence of Yoda1 (25 μM). Intracellular staining of IL-12p40. A representative figure shown on the left, and the data summarized on the right. The data are representative of three independent experiments (mean ± s.d.; n=3–4). **p&lt;0.01 and ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Piezo1 alters glycolytic metabolic signaling activities of dendritic cells (DCs).</title><p>Sorted splenic DCs from WT mice were stimulated with lipopolysaccharide (LPS) (10 ng/ml) or with 2 or 50 kPa hydrogels conditions for 24 hr in the presence or absence of 2-deoxy-D-glucose (2-DG) (1 mM) or Yoda1 (25 μM). (<bold>A</bold>) The proton production rate (PPR) was analyzed as a readout for glycolysis. (<bold>B</bold>) The oxygen consumption rate (OCR) was analyzed as a readout for oxidative phosphorylation (OXPHOS). (<bold>C</bold>) mRNA expression of glycolytic molecules in splenic DCs from WT mice in the presence of LPS (10 ng/ml) and Yoda1 (25 μM). Levels in the vehicle treatment at Glut1 group were set to 1. Data are representative of three independent experiments (mean ± s.d.; n=4). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Glycolysis activities are required for IL-12 and TGFβ1 production in dendritic cells (DCs) induced by Yoda1 treatment.</title><p>(<bold>A–B</bold>) Sorted splenic DCs from WT mice were stimulated with lipopolysaccharide (LPS) (10 ng/ml) or with 2 or 50 kPa hydrogels conditions for 24 hr in the presence or absence of 2-deoxy-D-glucose (2-DG) (1 mM) or Yoda1 (25 μM). Intracellular staining of IL-12p40 (<bold>A</bold>) and TGFβ1 (<bold>B</bold>) expression with indicated treatment. Data are representative of three independent experiments (mean ± s.d.; n=3). *p&lt;0.05 and ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Glycolytic metabolism activities are required for IL-12 and TGFβ1 production in dendritic cells (DCs) induced by Piezo1 deficiency.</title><p>(<bold>A</bold>) Sorted splenic DCs from WT or <italic>Piezo1</italic><sup>-/-</sup> mice were stimulated with lipopolysaccharide (LPS) (10 ng/ml) or 2 or 50 kPa hydrogels for 24 hr in the presence or absence of succinate (5 mM). The oxygen consumption rate (OCR) was analyzed as a readout for oxidative phosphorylation (OXPHOS). (<bold>B–C</bold>) Sorted splenic DCs from WT or <italic>Piezo1</italic><sup>-/-</sup> mice were stimulated with LPS (10 ng/ml) or with 50 kPa hydrogels conditions for 24 hr in the presence or absence of 2-DG (1 mM). Intracellular staining of IL-12p40 (<bold>B</bold>) and TGFβ1 (<bold>C</bold>) expression with indicated treatment. Data are representative of three independent experiments (mean ± s.d.; n=3). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig5-figsupp3-v2.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>TGFβ1, HIF1α, and glycolysis activity alteration in dendritic cells (DCs) induced by Piezo1 and SIRT1 deficiency.</title><p>Splenic DCs from WT, <italic>Piezo1</italic><sup>-/-</sup>, <italic>Sirt1</italic><sup>-/-</sup>, and Piezo1/Sirt1 double knockout (DKO) mice were stimulated with lipopolysaccharide (LPS) (10 ng/ml). (<bold>A</bold>) Intracellular staining of TGFβ1. (<bold>B</bold>) Intracellular staining of HIF1α. (<bold>C</bold>) Proton production rate (PPR) was analyzed as a readout for glycolysis. Data are representative of three independent experiments (mean ± s.d.; n=3–4). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig5-figsupp4-v2.tif"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 5.</label><caption><title>TGFβ1, SIRT1, and glycolysis activity alteration in dendritic cells (DCs) induced by Piezo1-HIF1α signaling.</title><p>Splenic DCs from WT or <italic>Hif1a</italic><sup>-/-</sup> mice were stimulated with lipopolysaccharide (LPS) (10 ng/ml) in the presence or absence of Yoda1 (25 μM). (<bold>A</bold>) Intracellular staining of TGFβ1. (<bold>B</bold>) Intracellular staining of SIRT1. (<bold>C</bold>) Proton production rate (PPR) was analyzed as a readout for glycolysis. Data are representative of three independent experiments (mean ± s.d.; n=3–4). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig5-figsupp5-v2.tif"/></fig></fig-group><p>Additionally, as expected, LPS activated all downstream pathways in WT DCs including p-JNK, p-Erk, p-p38, SIRT1, and HIF1α signal pathway. However, Piezo1 deletion in DCs enhanced the phosphorylation of Erk, p38, and JNK, similar to WT DCs. However, <italic>Piezo1</italic><sup>-/-</sup> DCs exhibited stronger and sustained activation of the histone deacetylase SIRT1 and weaker and shorter activation of the transcription factor HIF1α (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Thus, Piezo1 is probably associated with SIRT1-HIF1α signaling and glycolysis activation.</p><p>To determine whether SIRT1 is involved in this regulation, we used Piezo1 and SIRT1 double knockout (DKO) mice in this investigation. Interestingly, less IL-12 and more TGFβ1 production in <italic>Piezo1</italic><sup>-/-</sup> DCs was significantly reversed in Piezo1-SIRT1 DKO cells (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4A</xref>). Consistently, HIF1α expression and glycolysis activities were significantly recovered to a normal level (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4B-C</xref>). These data suggest that SIRT1 is required for the IL-12 and TGFβ1 production in DCs induced by Piezo1 and HIF1α and glycolysis activation is probably related with these alterations.</p><p>To determine whether HIF1α is involved in this regulation, we crossed DC HIF1α conditional knockout mice (<italic>Hif1a</italic><sup>-/-</sup>) with <italic>Hif1a</italic><sup>flox/flox</sup> and <italic>Cd11c-Cre</italic> mice. Splenic DCs were isolated from WT and <italic>Hif1a</italic><sup>-/-</sup> mice and treated with the Piezo1 agonist Yoda1. More IL-12 and less TGFβ1 in Yoda1-treated DCs was significantly reversed in Yoda1-treated <italic>Hif1a</italic><sup>-/-</sup> DCs (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, <xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5A</xref>). These data suggest that HIF1α is required for the IL-12 and TGFβ1 production in DCs induced by Piezo1.</p><p>Moreover, splenic DCs were treated with the Piezo1 agonist Yoda1, which significantly altered glycolysis activity and SIRT1 expression in DCs. SIRT1 expressions cannot be altered in <italic>Hif1a</italic><sup>-/-</sup> DCs (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5B</xref>). However, treatment of <italic>Hif1a</italic><sup>-/-</sup> with Yoda1 significantly reversed the alteration of glycolysis but not SIRT1 expression (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5B-C</xref>). Thus, HIF1α and glycolysis is downstream targets of SIRT1 in regulating the Piezo1-induced cytokine production in DCs.</p></sec><sec id="s2-9"><title>Piezo1 regulates IL-12 and TGFβ1 production through the calcium-calcineurin-NFAT axis</title><p>Mechanically activated ion channel Piezo1 regulates macrophage or DC function by altering calcium permeability (<xref ref-type="bibr" rid="bib2">Atcha et al., 2021</xref>; <xref ref-type="bibr" rid="bib4">Chakraborty et al., 2021</xref>). Therefore, we assessed the level of calcium influx in <italic>Piezo1</italic><sup>-/-</sup> splenic DCs. Inflammatory or stiffness stimulation caused a significant decrease in the calcium influx in <italic>Piezo1</italic><sup>-/-</sup> DCs compared with the WT control (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). And, Piezo1 agonist Yoda1 treatment significantly enhanced intracellular calcium influx, decreased TGFβ1 secretion, and increased IL-12 secretion by DCs exposed to LPS or conditioned by 50 kPa hydrogels (<xref ref-type="fig" rid="fig6">Figure 6B–D</xref>). Importantly, blocking the Ca<sup>2+</sup> signaling with ruthenium red reversed these alterations. But, another nonspecific ion channel inhibitor, gadolinium, had no effects on calcium influx or cytokine production in DCs (<xref ref-type="fig" rid="fig6">Figure 6B–D</xref>). Consistently, <italic>Piezo1</italic><sup>-/-</sup> DCs showed lower calcium influx and exhibited higher TGFβ1 and lower IL-12 levels, and blocking the Ca<sup>2+</sup> signaling pathway with ruthenium red, but not gadolinium reversed these alterations in cytokine production (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Thus, calcium signaling pathway is required for the TGFβ1 and IL-12 production in DCs induced by Piezo1.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Piezo1 regulates TGFβ1 and IL-12 production through the calcium-calcineurin-NFAT axis.</title><p>(<bold>A</bold>) Measurement of intracellular Ca<sup>2+</sup> concentrations with Fura2 dye in splenic dendritic cells (DCs) from WT or <italic>Piezo1</italic><sup>-/-</sup> mice treated with lipopolysaccharide (LPS) (10 ng/ml) or cultured on plates containing 50 kPa hydrogels. (<bold>B</bold>) Intracellular Ca<sup>2+</sup> concentrations measured with Fura2 in splenic DCs from WT mice after the indicated treatment (Yoda1, 25 μM, MCE; ruthenium red, 30 μM, Sigma; gadolinium chloride, 10 μM, Sigma). (<bold>C–D</bold>) Intracellular staining of TGFβ1 (<bold>C</bold>) and IL-12p40 (<bold>D</bold>) in splenic DCs from WT mice after the indicated treatments. (<bold>E</bold>) Intracellular staining of IL-12p40 in splenic DCs from WT mice after the indicated treatments. A representative figure shown on the left, and the data summarized on the right. (<bold>F</bold>) Intracellular staining of NFATc1 in splenic DCs from WT mice after the indicated treatments (CsA, 10 nM). A representative figure shown on the left, and data summarized on the right. (<bold>G–H</bold>) Intracellular staining of IL-12p40 in splenic DCs from WT or <italic>Piezo1</italic><sup>-/-</sup> mice after the indicated treatments (Yoda1, 25 μM, MCE; 11R-VIVIT, 100 nM, MCE; CsA, 10 nM, Sigma). A representative figure shown on the left, and data summarized on the right. The data are representative of three to four independent experiments (mean ± s.d.; n=3–4). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Piezo1 regulates TGFβ1 and IL-12 production through calcium signaling.</title><p>(<bold>A</bold>) Intracellular Ca<sup>2+</sup> using Fura2 in splenic dendritic cells (DCs) from WT or <italic>Piezo1</italic><sup>-/-</sup> mice with indicated treatment (Yoda1, 25 μM; ruthenium red, 30 μM; gadolinium chloride, 10 μM). (<bold>B–C</bold>) Intracellular staining of TGFβ1 (<bold>B</bold>) and IL-12p40 (<bold>C</bold>) in splenic DCs from WT or <italic>Piezo1</italic><sup>-/-</sup> mice with indicated treatments. Data are representative of three independent experiments (mean ± s.d.; n=3). ***p&lt;0.001, compared with the indicated groups. n.s., not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Piezo1 regulates TGFβ1 production through calcium-calcineurin-NFAT axis.</title><p>(A or C) Intracellular staining of TGFβ1 in splenic dendritic cells (DCs) from WT mice with indicated treatments. (<bold>B</bold>) Intracellular staining of TGFβ1 in splenic DCs from WT or <italic>Piezo1</italic><sup>-/-</sup> mice with indicated treatments (Yoda1, 25 μM; 11R-VIVIT, 100 nM; CsA, 10 nM). Data are representative of three to four independent experiments (mean ± s.d.; n=3–5). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig6-figsupp2-v2.tif"/></fig></fig-group><p>Previous studies have shown that calcineurin-NFAT are critical molecules of the calcium signaling pathway in regulating the immune response (<xref ref-type="bibr" rid="bib47">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Rudensky et al., 2006</xref>; <xref ref-type="bibr" rid="bib12">Hu et al., 2007</xref>; <xref ref-type="bibr" rid="bib44">Vaeth et al., 2012</xref>). These prompted us to investigate whether calcineurin-NFAT signals are necessary for Piezo1 to regulate DC function through calcium signaling pathway. Therefore, we pharmacologically targeted calcineurin and NFAT to assess their roles in regulating Piezo1-induced TGFβ1 and IL-12 production in DCs. Splenic DCs treated with the Piezo1 agonist Yoda1 caused more IL-12 and less TGFβ1 production, but blocking calcineurin with its inhibitor cyclosporin A (CsA) reversed these alterations in DCs (<xref ref-type="fig" rid="fig6">Figure 6E</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A</xref>). These data suggest that calcium-calcineurin signaling are probably required for cytokine productions in DCs induced by Piezo1.</p><p>As reported (<xref ref-type="bibr" rid="bib47">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Rudensky et al., 2006</xref>; <xref ref-type="bibr" rid="bib12">Hu et al., 2007</xref>; <xref ref-type="bibr" rid="bib44">Vaeth et al., 2012</xref>), NFAT is critical transcriptional factor for regulating calcium-calcineurin signaling pathway in mediating immune cell activities. Moreover, upregulation of Piezo1 with Yoda1 treatment enhanced the expression of NFAT, blocking calcineurin with CsA inhibits the expression of NFAT (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). To test the role of NFAT for Piezo1 to regulate DC function, we pharmacologically targeted NFAT with its inhibitor VIVT to assess the role of NFAT in regulating Piezo1-induced TGFβ1 and IL-12 production by DCs. <italic>Piezo1</italic><sup>-/-</sup> DCs exhibited less IL-12 and more TGFβ1, and blocking calcineurin with CsA and blocking NFAT with VIVIT consistently showed similar cytokine production by DCs (<xref ref-type="fig" rid="fig6">Figure 6G</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2B</xref>). Interestingly, splenic DCs treated with the Piezo1 agonist Yoda1 exhibited more IL-12 and less TGFβ1 production, but blocking NFAT with VIVIT reversed these alterations in DCs (<xref ref-type="fig" rid="fig6">Figure 6H</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2C</xref>). Altogether, these data suggest that the calcium-calcineurin-NFAT axis is required for regulating IL-12 and TGFβ1 production by DC Piezo1.</p></sec><sec id="s2-10"><title>IL-12 and TGFβ1 are critical for DC Piezo1-dependent T cell differentiation in promoting cancer growth</title><p>To test the significance of DC Piezo1-dependent T cell differentiation in anti-tumor immunity, IL-12 and anti-TGFβ1 antibody were locally injected into the tumor once a week to treat tumor-bearing mice. Although the rate of tumor growth was signiﬁcantly faster and greater in <italic>Piezo1</italic><sup>-/-</sup> than in WT mice, IL-12 or anti-TGFβ1 antibody treatment significantly inhibited the tumor growth caused by <italic>Piezo1</italic><sup>-/-</sup> (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Consistently, <italic>Piezo1</italic><sup>-/-</sup> tumor-bearing mice had more Foxp3<sup>+</sup> T<sub>reg</sub> cells and fewer IFNγ<sup>+</sup> T<sub>H</sub>1 cells in tumor tissue compared with WT control. However, IL-12 or anti-TGFβ1 antibody treatment reversed these alterations induced by <italic>Piezo1</italic><sup>-/-</sup> (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Thus, these data suggest that IL-12 and TGFβ1 are critical for DC Piezo1-dependent T cell differentiation in regulating cancer growth.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>IL-12 and TGFβ1 are critical for dendritic cell (DC) piezo1-dependent T cell differentiation in promoting cancer growth.</title><p>(<bold>A</bold>) MC38 tumor cells were implanted subcutaneously in WT and <italic>Piezo1</italic><sup>-/-</sup> mice (n=10), IL-12 100 ng or anti-TGFβ1 mAb 200 ng per mouse in 50 µl volume or vehicle (PBS) was locally injected into tumor once a week and tumor size was measured every 5 days for 40 days. (<bold>B</bold>) Intracellular staining of IFNγ, IL-17A, and Foxp3 expression in CD4<sup>+</sup> T cells from the tumor of WT and <italic>Piezo1</italic><sup>-/-</sup> tumor-bearing mice at day 40. (<bold>C</bold>) <italic>Piezo1</italic> mRNA expression of human DCs with the indicated treatment (lipopolysaccharide [LPS], 10 ng/ml or conditioned with 2 or 50 kPa hydrogels plate or LPS+50 kPa hydrogels plate). Levels in the vehicle group were set to 1. (<bold>D–E</bold>) IL-12p70 (<bold>D</bold>) and TGFβ1 (<bold>E</bold>) production of human DCs treated by LPS (10 ng/ml) for 5 hr. (<bold>F–H</bold>) Human DCs pulsed with LPS (10 ng/ml) were cocultured with human T cells for 5 days, in the absence or presence of Yoda1 (25 μM). The intracellular staining of IFNγ and Foxp3 in T cells. ***p&lt;0.001 compared with the indicated groups. Data are representative of three independent experiments (mean ± s.d.; n=3–4). ***p&lt;0.001, compared with the indicated groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Dendritic cell (DC) Piezo1 controls the differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cells in cancer.</title><p>Proposed model of how Piezo1 in DCs responses to inflammatory stimuli or stiffness signals to regulate the differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cell populations in regulating cancer growth.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79957-fig7-figsupp1-v2.tif"/></fig></fig-group><p>Next, we test to apply a pharmacological approach to target Piezo1 in human DCs and determine whether we can recapitulate our finding in genetic targeting Piezo1. Piezo1 expressions were determined in human DC cells, which is from human peripheral blood monocytes. Inflammatory LPS or 50 kPa-conditioned hydrogels alone or together significantly upregulated Piezo1 expressions (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Further, we applied Piezo1 agonist Yoda1 to human DC-T cell coculture system, whereby T cells were isolated from human cord blood. The pharmacological activation of Piezo1 in human DCs largely recapitulated what we observed in genetic mouse DCs in terms of the production of IL-12 and TGFβ1 in human DC (<xref ref-type="fig" rid="fig7">Figure 7D–E</xref>) and the alteration of Foxp3<sup>+</sup>T<sub>reg</sub> and IFNγ<sup>+</sup>T<sub>H</sub>1 in human T cells (<xref ref-type="fig" rid="fig7">Figure 7F–H</xref>). Thus, our data demonstrated that Piezo1 mediated an evolutionary conserved signaling pathway in both mouse and human DCs.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>DCs play a central role in initiating first-line innate immunity and inducing subsequent adaptive immunity in protecting against tumorigenesis (<xref ref-type="bibr" rid="bib30">Medzhitov et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">Steinman, 2012</xref>). As a professional APCs, DCs can efficiently shape antigen-specific adaptive immune responses by presenting various exogenous and endogenous antigen stimuli, regulating cell surface costimulatory molecule expression, and producing cytokines and chemokines (<xref ref-type="bibr" rid="bib16">Joffre et al., 2009</xref>; <xref ref-type="bibr" rid="bib14">Iwasaki and Medzhitov, 2010</xref>). Innate inflammatory stimuli include infectious factors, oxygen, nutrient availability, and even force and pressure, often change the DC responses and affect the immune outcome in diseases. Especially, tumor microenvironment usually integrates different innate inflammatory and stiffness stimuli and develop a complex stimulation microenvironment, but how does DC respond to inflammatory and stiffness stimuli and regulates T cell differentiation in tumor remains unclear. Here, our data revealed that the mechanical sensor Piezo1, a signal node, responds to innate inflammatory and/or stiffness stimuli and integrates both the SIRT1-HIF1α-glycolysis metabolic signaling axis and calcium-calcineurin-NFAT signaling in DCs to drive T<sub>H</sub>1 differentiation while inhibiting T<sub>reg</sub> lineage commitment in inhibiting tumor growth in the context of complex tumor microenvironment. The changes in IL-12Rβ2/TGFβR2 expression and downstream STAT4/SMAD3 signaling in responding T cells further result in strong DC-T cell crosstalk, indicating the differentiation of T<sub>reg</sub> and T<sub>H</sub>1 cells (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Thus, our results contribute to a more comprehensive understanding of the immunopathological process of DC Piezo1-directed T cell differentiation in the tumor microenvironment.</p><p>Recent studies have suggested that Piezo1 is involved in regulating many of diseases, including the infectious inflammation and cancer (<xref ref-type="bibr" rid="bib32">Nguetse et al., 2020</xref>; <xref ref-type="bibr" rid="bib7">Choi et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">Nonomura et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Chang et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Xie et al., 2022</xref>; <xref ref-type="bibr" rid="bib18">Kuriyama et al., 2022</xref>; <xref ref-type="bibr" rid="bib34">O’Callaghan et al., 2022</xref>; <xref ref-type="bibr" rid="bib26">Liu et al., 2021</xref>). Piezo1 modulates macrophage polarization and stiffness sensing, which are related to calcium influx and the promotion of macrophage activation by actin (<xref ref-type="bibr" rid="bib2">Atcha et al., 2021</xref>). The Piezo1-mediated response to LPS inflammatory stimulation regulates cell activation (<xref ref-type="bibr" rid="bib10">Geng et al., 2021</xref>). Global inhibition of Piezo1 with a peptide inhibitor showed protective effects against both cancer and septic shock (<xref ref-type="bibr" rid="bib3">Aykut et al., 2020</xref>). In addition to inflammatory stimulation, Piezo1 also showed immune regulatory effects on mechanical signals. Cyclical hydrostatic pressure initiates an inflammatory response via the mechanically activated ion channel Piezo1 (<xref ref-type="bibr" rid="bib40">Solis et al., 2019</xref>). Additionally, mechanical stiffness controls DC metabolism and function (<xref ref-type="bibr" rid="bib4">Chakraborty et al., 2021</xref>). Although these studies have clearly shown that Piezo1 respond to inflammatory stimulation as well as induce an immune response to mechanical stimulation and regulate immune cell functions, especially in innate immune cells, it is still unclear how to target DCs, to direct T cell differentiation in cancer. Our results showed that Piezo1 responds to inflammatory stimulation or stiffness signals, and subsequently, Piezo1 effectively integrates metabolism signals and ion signals pathway including SIRT1-HIF1α-glycolysis and the calcium-calcineurin-NFAT signaling pathway to direct the differentiation of T<sub>reg</sub> and T<sub>H</sub>1 cells by regulating the production of DC-derived polarizing cytokines, including IL-12 and TGFβ1, in the context of tumor microenvironment (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>).</p><p>Transcriptional factor HIF1α has been implicated as a critical proinflammatory signaling module in myeloid leukocytes (<xref ref-type="bibr" rid="bib8">Cramer et al., 2003</xref>; <xref ref-type="bibr" rid="bib36">Rius et al., 2008</xref>; <xref ref-type="bibr" rid="bib38">Sandau et al., 2001</xref>; <xref ref-type="bibr" rid="bib9">Dang et al., 2011</xref>; <xref ref-type="bibr" rid="bib51">Zhao et al., 2009</xref>; <xref ref-type="bibr" rid="bib28">McInturff et al., 2012</xref>). Consistent with recent findings that SIRT1 is responsible for the deacetylation and destabilization of HIF1α (<xref ref-type="bibr" rid="bib22">Lim et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Laemmle et al., 2012</xref>). HIF1α is critically involved in regulating Piezo1-induced innate immune cell function (<xref ref-type="bibr" rid="bib40">Solis et al., 2019</xref>). The metabolic mechanism is probably critical in regulating DC function (<xref ref-type="bibr" rid="bib4">Chakraborty et al., 2021</xref>). HIF1α-dependent glycolysis metabolism is also critical for regulating T<sub>H</sub>9 differentiation and MDSC development and function (<xref ref-type="bibr" rid="bib48">Wang et al., 2016</xref>). The present data showed that Piezo1 could target SIRT1-HIF1α-glycolysis metabolism signaling to modulate DC-derived polarizing cytokine secretion. Ion channel Piezo1 is sensitive to calcium influx in regulating immune cell function (<xref ref-type="bibr" rid="bib2">Atcha et al., 2021</xref>). These data also showed that blocking calcium influx significantly altered Piezo1-mediated DC-derived cytokine secretion. Previous studies have displayed the roles of calcineurin-NFAT in MDSCs in regulating T<sub>reg</sub> function (<xref ref-type="bibr" rid="bib47">Wang et al., 2015</xref>). Here, we further showed that Piezo1 targeting the calcineurin-NFAT axis modulates DC-derived polarizing cytokine production to direct T<sub>reg</sub> and T<sub>H</sub>1 cell differentiation in cancer.</p><p>Metabolic regulation and cellular signals are closely and generally associated with the immune response, but there are still few studies on the regulation of the calcium signaling pathway and immune response (<xref ref-type="bibr" rid="bib46">Wang and Green, 2012b</xref>; <xref ref-type="bibr" rid="bib11">Gerriets and Rathmell, 2012</xref>; <xref ref-type="bibr" rid="bib35">Pearce et al., 2013</xref>). Our data showed that Piezo1 integrate the metabolic signaling and calcium signaling pathways to modulate DC-derived polarizing cytokine production in the context of cancerous inflammation. Effective immune responses require DCs to function under various conditions, including altered extracellular mechanical tension states, intracellular metabolic states, and ion levels (possibly caused by inflammatory stimulation) or due to migration, nutritional, and/or hypoxic environments (tumor microenvironment). The adaptation of DCs to changing metabolic states and calcium signaling results from a mechanism of a ‘mechanical sensor checkpoint’, an active signaling process involved in sensing changes in metabolic and intracellular calcium levels and subsequent signaling transduction and execution (<xref ref-type="bibr" rid="bib45">Wang and Green, 2012a</xref>; <xref ref-type="bibr" rid="bib17">Kaelin, 2008</xref>; <xref ref-type="bibr" rid="bib39">Semenza, 2012</xref>; <xref ref-type="bibr" rid="bib13">Imai et al., 2000</xref>). Our data further suggested that the mechanical sensor Piezo1 in DCs requires the interplay of metabolic and intracellular calcium checkpoints, including the metabolic SIRT1-HIF1α-glycolysis pathway and a sensitive calcium signaling pathway, calcium-calcineurin-NFAT signaling. Therefore, Piezo1 modulator provides a new choice in the research of tumor immune microenvironment intervention, which takes DCs as the target to regulate T cell responses. For examples, Yoda1, a Piezo1 activator, can be used to respond to inflammatory and stiffness signals in tumors, and integrate a variety of intracellular signals to effectively direct T cell differentiation in protecting against tumor growth.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse: C57BL/6J (CD45.1 and CD45.2)</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse: <italic>Piezo1</italic><sup>flox/flox</sup></td><td align="left" valign="bottom">Jicuiyaokang company of China</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse: <italic>Cd11c</italic>-Cre</td><td align="left" valign="bottom">Nanfangmoshi biological company of China</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse: <italic>Piezo1</italic><sup>-/-</sup></td><td align="left" valign="bottom">Jicuiyaokang company of China</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse: <italic>Sirt1</italic><sup>flox/flox</sup></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse: <italic>Hif1a<sup>f</sup></italic><sup>lox/flox</sup></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse: <italic>Cd4</italic>-Cre</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Mouse: OTII TCR-transgenic mice</td><td align="left" valign="bottom">Jicuiyaokang company of China</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Primary mouse splenocyte cells</td><td align="left" valign="bottom">Beijing Normal University</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Freshly isolated from mice</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Primary mouse bone marrow cells</td><td align="left" valign="bottom">Beijing Normal University</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Freshly isolated from mice</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Primary mouse serum</td><td align="left" valign="bottom">Beijing Normal University</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Freshly isolated from mice</td></tr><tr><td align="left" valign="bottom">Cell line</td><td align="left" valign="bottom">Mouse colon cancer cell line MC-38</td><td align="left" valign="bottom">China cell bank ATCC Center</td><td align="left" valign="bottom">MC38</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line</td><td align="left" valign="bottom">Mouse melanoma cell line B16.F10</td><td align="left" valign="bottom">China cell bank ATCC Center</td><td align="left" valign="bottom">B16.F10</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line</td><td align="left" valign="bottom">Human DC</td><td align="left" valign="bottom">Lonza</td><td align="left" valign="bottom">CC-2701</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line</td><td align="left" valign="bottom">Human cord blood CD4<sup>+</sup> T cells</td><td align="left" valign="bottom">Lonza</td><td align="char" char="." valign="bottom">2C-200</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD11c FITC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat # MHCD11C01; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10373970">AB_10373970</ext-link></td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD11c APC eFluor780</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 47-0116-42</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD11c PE</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-0114-81</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD4 APC-Cy7</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat#130-109-536</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD8α FITC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 11-0081-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD11b FITC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 11-0112-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse Ly6G PE</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-9668-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse F4/80 PE</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-4801-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD19 PE</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-0199-42</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse TCR FITC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# TCR2730</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD44 FITC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 11-0441-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD62L APC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 11-0621-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD80 APC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 17-0801-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD54 FITC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 17-0549-42</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse MHCII APC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 17-5320-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse CD45 APC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 17-0459-42</td><td align="left" valign="bottom">FCS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse NK1.1 PE</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 25-5941-82</td><td align="left" valign="bottom">FCS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal Anti-mouse CCR7 APC</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A18389</td><td align="left" valign="bottom">FCS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-mouse PDL1 PE</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-5982-82</td><td align="left" valign="bottom">FCS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-mouse PDL2 PE</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-5986-82</td><td align="left" valign="bottom">FCS (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-mouse IFNγ PE</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-7311-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-mouse IL-4 PE</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-7041-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse Foxp3 PE</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-5773-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse IL-12p40</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-7123-82</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse TGFβ1</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-9829-42</td><td align="left" valign="bottom">FCS (1:100)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Fixation/Permeabilization Solution Kit</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat# 554714</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Mini Kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat# 74106</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">FastQuant RT Kit</td><td align="left" valign="bottom">Tiangen</td><td align="left" valign="bottom">Cat# KR106-02</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse IL-12 p70 Quantikine ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# M1270</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse TGF-beta 1 DuoSet ELISA</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY1679</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SuperReal PreMix Plus SYBR Green</td><td align="left" valign="bottom">Tiangen</td><td align="left" valign="bottom">Cat# FP205-02</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cyclosporin A</td><td align="left" valign="bottom">Signa-Aldrich</td><td align="left" valign="bottom">Cat# 59865-13-3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Yoda1</td><td align="left" valign="bottom">MCE</td><td align="left" valign="bottom">Cat# HY-18723</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="char" char="hyphen" valign="bottom">11R-VIVIT</td><td align="left" valign="bottom">MCE</td><td align="left" valign="bottom">Cat# HY-P1430</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Gadolinium chloride</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 19423-81-5</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ruthenium red</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 12790-48-6</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-Deoxy-D-glucose</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 29702-43-0</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Diethyl succinate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 123-25-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">IL-4</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# 204-IL</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">IL-12</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">Cat# 210–12</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fibronectin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# ECM001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Carbonyl cyanide-4-[trifluoromethoxy] phenylhydrazone</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# SML2959</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Rotenone</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# R8875</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fura2 AM</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 47989</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">LPS</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 2630</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Freund’s Adjuvant, Complete</td><td align="left" valign="bottom">Sigma–Aldrich</td><td align="left" valign="bottom">Cat# F5881</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PMA</td><td align="left" valign="bottom">Sigma-ALdrich</td><td align="left" valign="bottom">Cat# P8139</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ionomycin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# I0634</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">GM-CSF</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# 7954GM-010/CF</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Collagenase D</td><td align="left" valign="bottom">Worthington</td><td align="left" valign="bottom">Cat# LS005273</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Deoxyribonuclease I</td><td align="left" valign="bottom">Beyotime Biotechnology</td><td align="left" valign="bottom">Cat# D7076</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Percoll</td><td align="left" valign="bottom">GE Health</td><td align="left" valign="bottom">Cat# 17-0891-01</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Adobe Illustrator</td><td align="left" valign="bottom">Adobe</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_010279">SCR_010279</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">One-micrometer latex microspheres</td><td align="left" valign="bottom">Polysciences, Inc</td><td align="left" valign="bottom">Cat# 19821</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="char" char="hyphen" valign="bottom">7-AAD</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat# 559925 RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2869266">AB_2869266</ext-link></td><td align="left" valign="bottom">A dye for identifying cell death</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Streptavidin-APC/eFluor 780</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 47-4317-82; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10366688">AB_10366688</ext-link></td><td align="left" valign="bottom">A secondary antibody for indirect staining to detect biotinylated primary antibody; FCS (1:500)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Streptavidin-eFluor 450</td><td align="left" valign="bottom">Streptavidin-eFluor 450</td><td align="left" valign="bottom">Cat# 48-4317-82; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10359737">AB_10359737</ext-link></td><td align="left" valign="bottom">A secondary antibody for indirect staining to detect biotinylated primary antibody; FCS (1:500)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">SYLGARD 527 A&amp;B Silicone Dielectric Gel</td><td align="left" valign="bottom">Dow</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Silicone Dielectric Gel</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>All animal experiments were approved by the Animal Ethics Committee of Fudan University, Shanghai, China, Beijing Institute of Microbiology and Epidemiology and Beijing Normal University (IACUC-DWZX-2017-003 and CLS-EAW-2017-002) Beijing, China. C57BL/6 <italic>Piezo1</italic><sup>flox/flox</sup>, and <italic>Piezo1</italic><sup>-/-</sup> mice were obtained from Jicuiyaokang company of China (Nanjing, China). <italic>Cd11c-Cre</italic> mice were obtained from Nanfangmoshi biological company of China (Shanghai, China). <italic>Sirt1</italic><sup>flox/flox</sup> and <italic>Hif1a</italic><sup>flox/flox</sup> mice were obtained from the Jackson Laboratory (Bar Harbor, ME). OTII TCR-transgenic mice were obtained from Jicuiyaokang company of China (Nanjing, China). CD45.1 mouse was obtained from Beijing University Experimental Animal Center (Beijing, China). C57BL/6 mice were obtained from Fudan University Experimental Animal Center or Beijing University Experimental Animal Center (Beijing, China). All the mice had been backcrossed to the C57BL/6 background for at least eight generations and were used at an age of 6–12 weeks. WT control mice were of the same genetic background and, where relevant, included Cre<sup>+</sup> mice to account for the effects of Cre (no adverse effects due to Cre expression itself were observed in vitro or in vivo).</p></sec><sec id="s4-2"><title>Tumor model</title><p>To establish subcutaneous tumors, 5×10<sup>5</sup> MC38 or MC38-OVA tumor cells or 4×10<sup>5</sup> B16.F10 melanoma cells were injected into C57BL/6 mice, half male and half female, randomization group. These cells formed a tumor of 1–2 cm diameter within 2–4 weeks of injection and double blinding detection of mouse tumor size.</p></sec><sec id="s4-3"><title>T cell isolation from tumor</title><p>Tumor tissues were cut into pieces and suspended using collagenase D (Worthington, NJ; 400 U/ml) and deoxyribonuclease I (Beyotime Biotechnology, Shanghai, China; 4 U/ml) in 2 ml complete RPMI 1640 medium (Corning). After incubated for 30 min in a shaker at 37°C, the homogenized tissue was passed through a cell strainer (70 μm; BD Pharmingen). After centrifugation at 200× <italic>g</italic> for 5 min, the supernatant was discarded, and the pellet was resuspended with 3 ml of serum-free RPMI 1640. Add 3 ml 70% Percoll (GE Healthcare) to 15 ml centrifuge tube, then gently add 3 ml 40% Percoll to it, and finally slowly add 3 ml cell suspension to it to form a complete interface between the three layers. Centrifugation at 400× <italic>g</italic> for 25 min with slow acceleration and without breaks created a gradient. The interface cells between two density Perocoll (about 2–4 ml) were collected, washed with PBS for two times and stained with T cell antibodies for sorting by flow cytometry and prepared for further analysis.</p></sec><sec id="s4-4"><title>Cell isolation from gut-associated lymphatic tissues</title><p>Isolation of LPLs was performed as previously (<xref ref-type="bibr" rid="bib21">Li et al., 2017</xref>). The small intestine and large intestine were removed, opened longitudinally, and cut into pieces. After vigorous shaking in HBSS containing EDTA, the supernatants containing epithelial cells and IELs was discarded. The remaining intestinal pieces were digested with collagenase D (Worthington) and pelleted. The pellet was resuspended and placed in a Percoll gradient as described above, and after centrifugation, the interface containing the LPLs was collected and prepared for further analysis.</p></sec><sec id="s4-5"><title>Cell adoptive transfer</title><p>Naïve T cells (CD4<sup>+</sup>TCR<sup>+</sup>CD62L<sup>hi</sup>CD44<sup>lo</sup>CD25<sup>-</sup>) from C57BL/6 mice or OTII TCR-transgenic mice were sorted and transferred into recipient mice. After 24 hr, the recipient mice were injected s.c. with WT and <italic>Piezo1</italic><sup>-/-</sup> DCs mixed with OVA<sub>323-339</sub> in the presence of complete Freund’s adjuvant (CFA; Difco), LPS (Sigma), or 50 kPa hydrogel-conditioned DCs. At days 8–9 after immunization, DLN cells were harvested and stimulated with their cognate peptides for 2–3 days prior to cytokine mRNA expression and secretion analyses or pulsed with PMA-ionomycin for 5 hr prior to the intracellular staining of donor-derived T cells.</p></sec><sec id="s4-6"><title>Cell cultures and flow cytometry</title><p>Spleens were digested with collagenase D, and DCs (CD11c<sup>+</sup>TCR<sup>-</sup>CD19<sup>-</sup>NK1.1<sup>-</sup>F4/80<sup>-</sup>Ly6G<sup>-</sup>) were sorted with a FACSAria II (Becton Dickinson, San Diego, CA). Naïve T cells were sorted from spleen or PLN. For DC-T cell cocultures, DCs and T cells (1:10) were mixed in the presence of 1 μg/ml OVA<sub>323-339</sub> peptide and 100 ng/ml LPS. After 5 days of culture, live T cells were stimulated with PMA and ionomycin for intracellular cytokine staining or with plate-bound α-CD3 to measure cytokine secretion and mRNA expression. T cell proliferation was determined by pulsing cells with <sup>3</sup>H-thymidine for the final 12–16 hr of culture, as previously described (<xref ref-type="bibr" rid="bib23">Liu et al., 2009</xref>). For drug treatments, the cells were incubated with vehicle, CsA (10 nM; Sigma), Yoda1 (25 μM, MCE), 11R-VIVIT (100 nM, MCE), ruthenium red (30 μM, Sigma), gadolinium chloride (10 μM, Sigma), 2-DG (1 mmol/l, Sigma), or diethyl succinate (1 mmol/l, Sigma) for 0.5–1 hr before stimulation. For antibody or cytokine treatment, cultures were supplemented with IL-12 (10 μg/ml, Peprotech) and anti-TGFβ1 mAb (20 μg/ml, R&amp;D Systems). Flow cytometry was performed with the following antibodies from eBioscience, BD Biosciences, or Abcam: anti-CD11c FITC (N418), anti-CD11c PE (N418), anti-CD11c FITC (N418), anti-CD4 APC-Cy7 (GK1.5; Cat#130-109-536, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2657974">AB_2657974</ext-link>), anti-CD8α FITC (53–6.7), anti-CD11b FITC (M1/70), anti-Ly6G PE (RB6-8C5; Cat# ab25378, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_470493">AB_470493</ext-link>), anti-F4/80 PE (BM8), anti-CD19 PE (1D3; Cat#340418, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_400423">AB_400423</ext-link>), anti-TCR FITC (H57-597), anti-CD44 FITC (IM7), anti-CD62L APC (MEL14), anti-CD80 APC (1C10), anti-CD54 FITC (YN1/1/7.4), anti-MHCII (AF6-120), anti-CD45 APC (30-F11), anti-NK1.1 PE (PK136), anti-CCR7 APC (4B12, Cat#A18389, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2535249">AB_2535249</ext-link>), anti-PDL1 PE (MIH5, Cat# 12-5982-82), anti-PDL2 PE (TY25, Cat# 12-5986-82), anti-IFNγ PE (XMG1.2), anti-IL-4 PE (11B11), anti-Foxp3 PE (FJK-16s), anti-mouse IL-12p40 mAb (241812; Cat#BE0051, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1107698">AB_1107698</ext-link>), and anti-mouse TGFβ1 mAb (EPR21143). Flow cytometry data were acquired on a FACSCalibur (Becton Dickinson, CA) and the data were analyzed with FlowJo (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link>; Tree Star, San Carlos, CA).</p></sec><sec id="s4-7"><title>Phagocytosis assay</title><p>One-micrometer latex microspheres (Polysciences, Inc) were incubated overnight with 1 mg/ml of mouse IgG-FITC (Jackson ImmunoResearch Laboratories). After rinsing the unbound antibody, the microspheres were added to DCs cultured at a ratio between DC and beads is 1:10 and incubated for 30 min in a humidified incubator at 37°C and 5% CO<sub>2</sub>. Unbound or attached noninternalized beads were washed in consecutive rinsing steps with cold PBS. DCs were then stained with anti-CD11c, rinsed in cold PBS. The phagocytosis percentage of DCs were determined with flow cytometry.</p></sec><sec id="s4-8"><title>Hydrogel-coated plates</title><p>Dow Corning Sylgard 527 (Parts A and B, Sigma-Aldrich) was used to prepare PDMS hydrogel-coated plates. Part A and Part B of the gel were mixed to achieve the appropriate tension, as described (<xref ref-type="bibr" rid="bib40">Solis et al., 2019</xref>; <xref ref-type="bibr" rid="bib4">Chakraborty et al., 2021</xref>; <xref ref-type="bibr" rid="bib25">Liu et al., 2018</xref>). For the 2 kPa gel, the ratio of A:B was 1:2, and for the 50 kPa gel, the ratio of A:B was 0.3. The plates were coated with the hydrogel and incubated overnight at 60°C. Then, the gels were coated with fibronectin (1 μg/ml, Sigma) for 4 hr at 37°C and washed again with PBS.</p></sec><sec id="s4-9"><title>Oxygen consumption analysis</title><p>Cells were plated in 24-well Seahorse plates at 2×10<sup>5</sup> cells per well, and a negative control well containing only media without cells was included. A utility plate containing calibrant solution (1 ml/well) together with the plates containing the injector ports and probes was incubated in a CO<sub>2</sub>-free incubator at 37°C overnight. The following day, the medium was removed from the cells and replaced with glucose-supplemented XF assay buffer (500 μl/well), and the cell culture plate was incubated in a CO<sub>2</sub>-free incubator for at least 0.5 hr. Inhibitors (oligomycin, carbonyl cyanide-4-[trifluoromethoy]) phenylhydrazone, 2-DG, and rotenone (70 μl) were added to the appropriate port of the injector plate. This plate, together with the utility plate, was run on the Seahorse for calibration. Then, the utility plate was replaced with the cell culture plate, and the cell culture plate was analyzed on the Seahorse XF-24 instrument.</p></sec><sec id="s4-10"><title>Measurement of intracellular Ca<sup>2+</sup> concentrations</title><p>The intracellular Ca<sup>2+</sup> concentrations ([Ca<sup>2+</sup>]) were measured fluorometrically using the fluorescent calcium indicator dye Fura2 AM (Sigma), as previously described (<xref ref-type="bibr" rid="bib2">Atcha et al., 2021</xref>). Cells were incubated with 5 μM Fura2 AM in HBSS supplemented with 110 mM NaCl, 5 mM KCl, 0.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 0.4 M KH<sub>2</sub>PO<sub>4</sub>, 5.6 mM glucose, 0.8 mM MgSO<sub>4</sub>, 7 mM H<sub>2</sub>O, 4 mM NaHCO<sub>3</sub>, 1.26 mM CaCl<sub>2</sub>, and 15 mM HEPE, at pH 7.4, at room temperature for 60 min.</p></sec><sec id="s4-11"><title>RNA and protein expression analysis</title><p>RNA was extracted with a RNeasy kit (QIAGEN, Dusseldorf, Germany), and cDNA was synthesized using SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA). An ABI 7900 real-time PCR system was used for quantitative PCR, with primer and probe sets obtained from Applied Biosystems (Carlsbad, CA). The results were analyzed using SDS 2.1 software (Applied Biosystems). The cycling threshold value of the endogenous control gene (<italic>Hprt</italic>1, which encodes hypoxanthine guanine phosphoribosyl transferase) was subtracted from the cycling threshold (ΔC<sub>T</sub>). The expression of each target gene is presented as the fold change relative to that of control samples (2-<sup>ΔΔCT</sup>). For the detection of phosphorylated signaling proteins, purified cells were activated with LPS (Sigma), immediately fixed with Phosflow Perm buffer (BD Biosciences) and stained with phycoerythrin or allophycocyanin directly conjugated to antibodies against Erk phosphorylated at Thr202 and Tyr204 (20A; Cat# 612566, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_399857">AB_399857</ext-link>; BD Biosciences), p38MAPK phosphorylated at Thr180 and Thr182 (D3F9; Cell Signaling Technology), JNK phosphorylated at Thr183 and Tyr185 (G9; Cell Signaling Technology), STAT4 phosphorylated at Tyr701 and Ser727 (58D6; Cell Signaling Technology), and SMAD3 phosphorylated at Tyr705 and Ser727 (D3A7; Cell Signaling Technology), as described (<xref ref-type="bibr" rid="bib23">Liu et al., 2009</xref>). Intracellular staining analysis was performed as described (<xref ref-type="bibr" rid="bib21">Li et al., 2017</xref>) using anti-HIF-1α (EPR16897; Abcam) and anti-SIRT1 (19A7AB4; Abcam) antibodies.</p></sec><sec id="s4-12"><title>IL-12Rβ2 and TGFβR2 knockdown with RNAi</title><p>A gene-knockdown lentiviral construct was generated by subcloning gene-specific short hairpin RNA (shRNA) sequences into lentiviral shRNA expression plasmids (pMagic4.1) as described (<xref ref-type="bibr" rid="bib48">Wang et al., 2016</xref>). Lentiviruses were harvested from the culture supernatant of 293T cells (KCB Cat# KCB 200744YJ, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0063">CVCL_0063</ext-link>) transfected with shRNA vector. Sorted OTII CD4<sup>+</sup> T cells were infected with the recombinant lentivirus, and green fluorescent protein-expressing cells were isolated using fluorescence sorting 48 hr later. IL-12Rβ2 and TGFβR2 expression was confirmed using real-time PCR. The sorted T cells expressing either control or shRNA vectors were used for functional assays.</p></sec><sec id="s4-13"><title>Human DC and T cell cultures</title><p>For assays of human DC-mediated T cell differentiation, normal human DCs (CC-2701; Lonza) were cultured and their populations were expanded for 5 days with human granulocyte-macrophage colony-stimulating factor and IL-4 (R&amp;D Systems), followed by treatment with Yoda1 (25 μM, MCE) and stimulation for 24 hr with LPS. DCs were washed extensively and cultured with human cord blood CD4<sup>+</sup> T cells (2C-200; Lonza) at a ratio of 1:10. After 7 days of culture, live T cells were purified and then stimulated either with PMA and ionomycin for intracellular cytokine staining for 5 hr or with plate-bound anti-CD3 for analysis of mRNA expression.</p></sec><sec id="s4-14"><title>Statistical analysis</title><p>All the data are presented as the mean ± s.d. Student’s unpaired <italic>t</italic> test was used for the comparison of means to evaluate differences between groups. A p value (alpha-value) of less than 0.05 was considered statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Investigation, Project administration</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Participating in discussion</p></fn><fn fn-type="con" id="con5"><p>Participating in discussion</p></fn><fn fn-type="con" id="con6"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Participating in discussion</p></fn><fn fn-type="con" id="con8"><p>Participating in discussion</p></fn><fn fn-type="con" id="con9"><p>Participating in discussion</p></fn><fn fn-type="con" id="con10"><p>Resources, Data curation, Supervision, Investigation</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Normal human DCs (CC-2701; Lonza) and human cord blood CD4<sup>+</sup> T cells (2C-200; Lonza) were obtained from Lonza Company. All human subject experiments were performed with the approval of the Ethics Committee of of Fudan University, China and Beijing Normal University, China.</p></fn><fn fn-type="other"><p>All animal experiments were approved by the Animal Ethics Committee of Fudan University, Shanghai, China, Beijing Institute of Microbiology and Epidemiology and Beijing Normal University (IACUC-DWZX-2017-003 and CLS-EAW-2017-002).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-79957-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files; source data files have been provided for Figure1.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors’ research is supported by grants from the National Natural Science Foundation for Key Programs of China (31730024, GL), National Natural Science Foundation for General Programs of China (32170911, GL and 31970863, YB), and Beijing Municipal Natural Science Foundation of China (5202013, GL).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adorini</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes</article-title><source>Annals of the New York Academy of Sciences</source><volume>987</volume><fpage>258</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2003.tb06057.x</pub-id><pub-id pub-id-type="pmid">12727648</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atcha</surname><given-names>H</given-names></name><name><surname>Jairaman</surname><given-names>A</given-names></name><name><surname>Holt</surname><given-names>JR</given-names></name><name><surname>Meli</surname><given-names>VS</given-names></name><name><surname>Nagalla</surname><given-names>RR</given-names></name><name><surname>Veerasubramanian</surname><given-names>PK</given-names></name><name><surname>Brumm</surname><given-names>KT</given-names></name><name><surname>Lim</surname><given-names>HE</given-names></name><name><surname>Othy</surname><given-names>S</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name><name><surname>Pathak</surname><given-names>MM</given-names></name><name><surname>Liu</surname><given-names>WF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mechanically activated ion channel piezo1 modulates macrophage polarization and stiffness sensing</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3256</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23482-5</pub-id><pub-id pub-id-type="pmid">34059671</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aykut</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>JI</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Shadaloey</surname><given-names>SAA</given-names></name><name><surname>Abengozar</surname><given-names>R</given-names></name><name><surname>Preiss</surname><given-names>P</given-names></name><name><surname>Saxena</surname><given-names>A</given-names></name><name><surname>Pushalkar</surname><given-names>S</given-names></name><name><surname>Leinwand</surname><given-names>J</given-names></name><name><surname>Diskin</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Werba</surname><given-names>G</given-names></name><name><surname>Berman</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>SKB</given-names></name><name><surname>Khodadadi-Jamayran</surname><given-names>A</given-names></name><name><surname>Saxena</surname><given-names>D</given-names></name><name><surname>Coetzee</surname><given-names>WA</given-names></name><name><surname>Miller</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting piezo1 unleashes innate immunity against cancer and infectious disease</article-title><source>Science Immunology</source><volume>5</volume><elocation-id>50</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abb5168</pub-id><pub-id pub-id-type="pmid">32826342</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>M</given-names></name><name><surname>Chu</surname><given-names>K</given-names></name><name><surname>Shrestha</surname><given-names>A</given-names></name><name><surname>Revelo</surname><given-names>XS</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Gold</surname><given-names>MJ</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Akbari</surname><given-names>M</given-names></name><name><surname>Barrow</surname><given-names>F</given-names></name><name><surname>Chan</surname><given-names>YT</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Kotoulas</surname><given-names>NK</given-names></name><name><surname>Jovel</surname><given-names>J</given-names></name><name><surname>Pastrello</surname><given-names>C</given-names></name><name><surname>Kotlyar</surname><given-names>M</given-names></name><name><surname>Goh</surname><given-names>C</given-names></name><name><surname>Michelakis</surname><given-names>E</given-names></name><name><surname>Clemente-Casares</surname><given-names>X</given-names></name><name><surname>Ohashi</surname><given-names>PS</given-names></name><name><surname>Engleman</surname><given-names>EG</given-names></name><name><surname>Winer</surname><given-names>S</given-names></name><name><surname>Jurisica</surname><given-names>I</given-names></name><name><surname>Tsai</surname><given-names>S</given-names></name><name><surname>Winer</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mechanical stiffness controls dendritic cell metabolism and function</article-title><source>Cell Reports</source><volume>34</volume><elocation-id>108609</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108609</pub-id><pub-id pub-id-type="pmid">33440149</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JE</given-names></name><name><surname>Buechler</surname><given-names>MB</given-names></name><name><surname>Gressier</surname><given-names>E</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Carroll</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mechanosensing by peyer’s patch stroma regulates lymphocyte migration and mucosal antibody responses</article-title><source>Nature Immunology</source><volume>20</volume><fpage>1506</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0505-z</pub-id><pub-id pub-id-type="pmid">31611698</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulation and function of mtor signalling in T cell fate decisions</article-title><source>Nature Reviews. Immunology</source><volume>12</volume><fpage>325</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/nri3198</pub-id><pub-id pub-id-type="pmid">22517423</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>E</given-names></name><name><surname>Jung</surname><given-names>E</given-names></name><name><surname>Cha</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>PM</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>YJ</given-names></name><name><surname>Koh</surname><given-names>CJ</given-names></name><name><surname>Cho</surname><given-names>C-W</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Li Jeon</surname><given-names>N</given-names></name><name><surname>Wong</surname><given-names>AK</given-names></name><name><surname>Shin</surname><given-names>L</given-names></name><name><surname>Kumar</surname><given-names>SR</given-names></name><name><surname>Bermejo-Moreno</surname><given-names>I</given-names></name><name><surname>Srinivasan</surname><given-names>RS</given-names></name><name><surname>Cho</surname><given-names>I-T</given-names></name><name><surname>Hong</surname><given-names>Y-K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Piezo1 incorporates mechanical force signals into the genetic program that governs lymphatic valve development and maintenance</article-title><source>JCI Insight</source><volume>4</volume><elocation-id>125068</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.125068</pub-id><pub-id pub-id-type="pmid">30676326</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cramer</surname><given-names>T</given-names></name><name><surname>Yamanishi</surname><given-names>Y</given-names></name><name><surname>Clausen</surname><given-names>BE</given-names></name><name><surname>Förster</surname><given-names>I</given-names></name><name><surname>Pawlinski</surname><given-names>R</given-names></name><name><surname>Mackman</surname><given-names>N</given-names></name><name><surname>Haase</surname><given-names>VH</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name><name><surname>Corr</surname><given-names>M</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name><name><surname>Firestein</surname><given-names>GS</given-names></name><name><surname>Gerber</surname><given-names>HP</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Johnson</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>HIF-1alpha is essential for myeloid cell-mediated inflammation</article-title><source>Cell</source><volume>112</volume><fpage>645</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(03)00154-5</pub-id><pub-id pub-id-type="pmid">12628185</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>EV</given-names></name><name><surname>Barbi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H-Y</given-names></name><name><surname>Jinasena</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Bordman</surname><given-names>Z</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Yen</surname><given-names>H-R</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Zeller</surname><given-names>K</given-names></name><name><surname>Shimoda</surname><given-names>L</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Dang</surname><given-names>CV</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Pan</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1</article-title><source>Cell</source><volume>146</volume><fpage>772</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.07.033</pub-id><pub-id pub-id-type="pmid">21871655</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>F</given-names></name><name><surname>Hong</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TLR4 signalling via piezo1 engages and enhances the macrophage mediated host response during bacterial infection</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3519</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23683-y</pub-id><pub-id pub-id-type="pmid">34112781</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerriets</surname><given-names>VA</given-names></name><name><surname>Rathmell</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Metabolic pathways in T cell fate and function</article-title><source>Trends in Immunology</source><volume>33</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.it.2012.01.010</pub-id><pub-id pub-id-type="pmid">22342741</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Djuretic</surname><given-names>I</given-names></name><name><surname>Sundrud</surname><given-names>MS</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Transcriptional partners in regulatory T cells: foxp3, runx and NFAT</article-title><source>Trends in Immunology</source><volume>28</volume><fpage>329</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.it.2007.06.006</pub-id><pub-id pub-id-type="pmid">17618833</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>S</given-names></name><name><surname>Armstrong</surname><given-names>CM</given-names></name><name><surname>Kaeberlein</surname><given-names>M</given-names></name><name><surname>Guarente</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Transcriptional silencing and longevity protein sir2 is an NAD-dependent histone deacetylase</article-title><source>Nature</source><volume>403</volume><fpage>795</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1038/35001622</pub-id><pub-id pub-id-type="pmid">10693811</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regulation of adaptive immunity by the innate immune system</article-title><source>Science</source><volume>327</volume><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1126/science.1183021</pub-id><pub-id pub-id-type="pmid">20075244</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jairaman</surname><given-names>A</given-names></name><name><surname>Othy</surname><given-names>S</given-names></name><name><surname>Dynes</surname><given-names>JL</given-names></name><name><surname>Yeromin</surname><given-names>AV</given-names></name><name><surname>Zavala</surname><given-names>A</given-names></name><name><surname>Greenberg</surname><given-names>ML</given-names></name><name><surname>Nourse</surname><given-names>JL</given-names></name><name><surname>Holt</surname><given-names>JR</given-names></name><name><surname>Cahalan</surname><given-names>SM</given-names></name><name><surname>Marangoni</surname><given-names>F</given-names></name><name><surname>Parker</surname><given-names>I</given-names></name><name><surname>Pathak</surname><given-names>MM</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Piezo1 channels restrain regulatory T cells but are dispensable for effector CD4<sup>+</sup> T cell responses</article-title><source>Science Advances</source><volume>7</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abg5859</pub-id><pub-id pub-id-type="pmid">34233878</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joffre</surname><given-names>O</given-names></name><name><surname>Nolte</surname><given-names>MA</given-names></name><name><surname>Spörri</surname><given-names>R</given-names></name><name><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inflammatory signals in dendritic cell activation and the induction of adaptive immunity</article-title><source>Immunological Reviews</source><volume>227</volume><fpage>234</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00718.x</pub-id><pub-id pub-id-type="pmid">19120488</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaelin</surname><given-names>WG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The von hippel-lindau tumour suppressor protein: O2 sensing and cancer</article-title><source>Nature Reviews. Cancer</source><volume>8</volume><fpage>865</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1038/nrc2502</pub-id><pub-id pub-id-type="pmid">18923434</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuriyama</surname><given-names>M</given-names></name><name><surname>Hirose</surname><given-names>H</given-names></name><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Shudou</surname><given-names>M</given-names></name><name><surname>Arafiles</surname><given-names>JVV</given-names></name><name><surname>Imanishi</surname><given-names>M</given-names></name><name><surname>Maekawa</surname><given-names>M</given-names></name><name><surname>Hara</surname><given-names>Y</given-names></name><name><surname>Futaki</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Piezo1 activation using yoda1 inhibits macropinocytosis in A431 human epidermoid carcinoma cells</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>6322</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-10153-8</pub-id><pub-id pub-id-type="pmid">35428847</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laemmle</surname><given-names>A</given-names></name><name><surname>Lechleiter</surname><given-names>A</given-names></name><name><surname>Roh</surname><given-names>V</given-names></name><name><surname>Schwarz</surname><given-names>C</given-names></name><name><surname>Portmann</surname><given-names>S</given-names></name><name><surname>Furer</surname><given-names>C</given-names></name><name><surname>Keogh</surname><given-names>A</given-names></name><name><surname>Tschan</surname><given-names>MP</given-names></name><name><surname>Candinas</surname><given-names>D</given-names></name><name><surname>Vorburger</surname><given-names>SA</given-names></name><name><surname>Stroka</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1α protein under hypoxic conditions</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e33433</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0033433</pub-id><pub-id pub-id-type="pmid">22479397</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>MO</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TGF-beta: a master of all T cell trades</article-title><source>Cell</source><volume>134</volume><fpage>392</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.07.025</pub-id><pub-id pub-id-type="pmid">18692464</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Jia</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dendritic cell MST1 inhibits th17 differentiation</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14275</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14275</pub-id><pub-id pub-id-type="pmid">28145433</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J-H</given-names></name><name><surname>Lee</surname><given-names>Y-M</given-names></name><name><surname>Chun</surname><given-names>Y-S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>J-E</given-names></name><name><surname>Park</surname><given-names>J-W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha</article-title><source>Molecular Cell</source><volume>38</volume><fpage>864</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.023</pub-id><pub-id pub-id-type="pmid">20620956</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Burns</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Boyd</surname><given-names>K</given-names></name><name><surname>Proia</surname><given-names>RL</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The receptor S1P1 overrides regulatory T cell-mediated immune suppression through akt-mtor</article-title><source>Nature Immunology</source><volume>10</volume><fpage>769</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1038/ni.1743</pub-id><pub-id pub-id-type="pmid">19483717</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Burns</surname><given-names>S</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The S1P(1)-mtor axis directs the reciprocal differentiation of T(H)1 and T(reg) cells</article-title><source>Nature Immunology</source><volume>11</volume><fpage>1047</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1038/ni.1939</pub-id><pub-id pub-id-type="pmid">20852647</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CSC</given-names></name><name><surname>Raychaudhuri</surname><given-names>D</given-names></name><name><surname>Paul</surname><given-names>B</given-names></name><name><surname>Chakrabarty</surname><given-names>Y</given-names></name><name><surname>Ghosh</surname><given-names>AR</given-names></name><name><surname>Rahaman</surname><given-names>O</given-names></name><name><surname>Talukdar</surname><given-names>A</given-names></name><name><surname>Ganguly</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cutting edge: piezo1 mechanosensors optimize human T cell activation</article-title><source>Journal of Immunology</source><volume>200</volume><fpage>1255</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1701118</pub-id><pub-id pub-id-type="pmid">29330322</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>B</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Piezo1 impairs hepatocellular tumor growth via deregulation of the MAPK-mediated YAP signaling pathway</article-title><source>Cell Calcium</source><volume>95</volume><elocation-id>102367</elocation-id><pub-id pub-id-type="doi">10.1016/j.ceca.2021.102367</pub-id><pub-id pub-id-type="pmid">33610907</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin</surname><given-names>E</given-names></name><name><surname>Bouchet-Delbos</surname><given-names>L</given-names></name><name><surname>Renoult</surname><given-names>O</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Nerriere-Daguin</surname><given-names>V</given-names></name><name><surname>Managh</surname><given-names>AJ</given-names></name><name><surname>Even</surname><given-names>A</given-names></name><name><surname>Giraud</surname><given-names>M</given-names></name><name><surname>Vu Manh</surname><given-names>TP</given-names></name><name><surname>Aguesse</surname><given-names>A</given-names></name><name><surname>Bériou</surname><given-names>G</given-names></name><name><surname>Chiffoleau</surname><given-names>E</given-names></name><name><surname>Alliot-Licht</surname><given-names>B</given-names></name><name><surname>Prieur</surname><given-names>X</given-names></name><name><surname>Croyal</surname><given-names>M</given-names></name><name><surname>Hutchinson</surname><given-names>JA</given-names></name><name><surname>Obermajer</surname><given-names>N</given-names></name><name><surname>Geissler</surname><given-names>EK</given-names></name><name><surname>Vanhove</surname><given-names>B</given-names></name><name><surname>Blancho</surname><given-names>G</given-names></name><name><surname>Dalod</surname><given-names>M</given-names></name><name><surname>Josien</surname><given-names>R</given-names></name><name><surname>Pecqueur</surname><given-names>C</given-names></name><name><surname>Cuturi</surname><given-names>M-C</given-names></name><name><surname>Moreau</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human tolerogenic dendritic cells regulate immune responses through lactate synthesis</article-title><source>Cell Metabolism</source><volume>30</volume><fpage>1075</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.11.011</pub-id><pub-id pub-id-type="pmid">31801055</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McInturff</surname><given-names>AM</given-names></name><name><surname>Cody</surname><given-names>MJ</given-names></name><name><surname>Elliott</surname><given-names>EA</given-names></name><name><surname>Glenn</surname><given-names>JW</given-names></name><name><surname>Rowley</surname><given-names>JW</given-names></name><name><surname>Rondina</surname><given-names>MT</given-names></name><name><surname>Yost</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α</article-title><source>Blood</source><volume>120</volume><fpage>3118</fpage><lpage>3125</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-01-405993</pub-id><pub-id pub-id-type="pmid">22919032</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKinstry</surname><given-names>KK</given-names></name><name><surname>Strutt</surname><given-names>TM</given-names></name><name><surname>Swain</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regulation of CD4+ T-cell contraction during pathogen challenge</article-title><source>Immunological Reviews</source><volume>236</volume><fpage>110</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00921.x</pub-id><pub-id pub-id-type="pmid">20636812</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Shevach</surname><given-names>EM</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Mellor</surname><given-names>AL</given-names></name><name><surname>Munn</surname><given-names>DH</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name><name><surname>Shortman</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Gabrilovich</surname><given-names>D</given-names></name><name><surname>Gabryšová</surname><given-names>L</given-names></name><name><surname>Howes</surname><given-names>A</given-names></name><name><surname>O’Garra</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Highlights of 10 years of immunology in nature reviews immunology</article-title><source>Nature Reviews. Immunology</source><volume>11</volume><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1038/nri3063</pub-id><pub-id pub-id-type="pmid">21941295</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Stockinger</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Effector T cell plasticity: flexibility in the face of changing circumstances</article-title><source>Nature Immunology</source><volume>11</volume><fpage>674</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/ni.1899</pub-id><pub-id pub-id-type="pmid">20644573</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguetse</surname><given-names>CN</given-names></name><name><surname>Purington</surname><given-names>N</given-names></name><name><surname>Ebel</surname><given-names>ER</given-names></name><name><surname>Shakya</surname><given-names>B</given-names></name><name><surname>Tetard</surname><given-names>M</given-names></name><name><surname>Kremsner</surname><given-names>PG</given-names></name><name><surname>Velavan</surname><given-names>TP</given-names></name><name><surname>Egan</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A common polymorphism in the mechanosensitive ion channel PIEZO1 is associated with protection from severe malaria in humans</article-title><source>PNAS</source><volume>117</volume><fpage>9074</fpage><lpage>9081</lpage><pub-id pub-id-type="doi">10.1073/pnas.1919843117</pub-id><pub-id pub-id-type="pmid">32265284</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonomura</surname><given-names>K</given-names></name><name><surname>Lukacs</surname><given-names>V</given-names></name><name><surname>Sweet</surname><given-names>DT</given-names></name><name><surname>Goddard</surname><given-names>LM</given-names></name><name><surname>Kanie</surname><given-names>A</given-names></name><name><surname>Whitwam</surname><given-names>T</given-names></name><name><surname>Ranade</surname><given-names>SS</given-names></name><name><surname>Fujimori</surname><given-names>T</given-names></name><name><surname>Kahn</surname><given-names>ML</given-names></name><name><surname>Patapoutian</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanically activated ion channel PIEZO1 is required for lymphatic valve formation</article-title><source>PNAS</source><volume>115</volume><fpage>12817</fpage><lpage>12822</lpage><pub-id pub-id-type="doi">10.1073/pnas.1817070115</pub-id><pub-id pub-id-type="pmid">30482854</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Callaghan</surname><given-names>P</given-names></name><name><surname>Engberg</surname><given-names>A</given-names></name><name><surname>Eriksson</surname><given-names>O</given-names></name><name><surname>Fatsis-Kavalopoulos</surname><given-names>N</given-names></name><name><surname>Stelzl</surname><given-names>C</given-names></name><name><surname>Sanchez</surname><given-names>G</given-names></name><name><surname>Idevall-Hagren</surname><given-names>O</given-names></name><name><surname>Kreuger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Piezo1 activation attenuates thrombin-induced blebbing in breast cancer cells</article-title><source>Journal of Cell Science</source><volume>135</volume><elocation-id>jcs258809</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.258809</pub-id><pub-id pub-id-type="pmid">35274124</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>EL</given-names></name><name><surname>Poffenberger</surname><given-names>MC</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Jones</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Fueling immunity: insights into metabolism and lymphocyte function</article-title><source>Science</source><volume>342</volume><elocation-id>1242454</elocation-id><pub-id pub-id-type="doi">10.1126/science.1242454</pub-id><pub-id pub-id-type="pmid">24115444</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rius</surname><given-names>J</given-names></name><name><surname>Guma</surname><given-names>M</given-names></name><name><surname>Schachtrup</surname><given-names>C</given-names></name><name><surname>Akassoglou</surname><given-names>K</given-names></name><name><surname>Zinkernagel</surname><given-names>AS</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name><name><surname>Johnson</surname><given-names>RS</given-names></name><name><surname>Haddad</surname><given-names>GG</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>NF-kappab links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha</article-title><source>Nature</source><volume>453</volume><fpage>807</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1038/nature06905</pub-id><pub-id pub-id-type="pmid">18432192</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudensky</surname><given-names>AY</given-names></name><name><surname>Gavin</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>FOXP3 and NFAT: partners in tolerance</article-title><source>Cell</source><volume>126</volume><fpage>253</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.07.005</pub-id><pub-id pub-id-type="pmid">16873058</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandau</surname><given-names>KB</given-names></name><name><surname>Fandrey</surname><given-names>J</given-names></name><name><surname>Brüne</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Accumulation of HIF-1alpha under the influence of nitric oxide</article-title><source>Blood</source><volume>97</volume><fpage>1009</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1182/blood.v97.4.1009</pub-id><pub-id pub-id-type="pmid">11159530</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hypoxia-inducible factors in physiology and medicine</article-title><source>Cell</source><volume>148</volume><fpage>399</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.01.021</pub-id><pub-id pub-id-type="pmid">22304911</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solis</surname><given-names>AG</given-names></name><name><surname>Bielecki</surname><given-names>P</given-names></name><name><surname>Steach</surname><given-names>HR</given-names></name><name><surname>Sharma</surname><given-names>L</given-names></name><name><surname>Harman</surname><given-names>CCD</given-names></name><name><surname>Yun</surname><given-names>S</given-names></name><name><surname>de Zoete</surname><given-names>MR</given-names></name><name><surname>Warnock</surname><given-names>JN</given-names></name><name><surname>To</surname><given-names>SDF</given-names></name><name><surname>York</surname><given-names>AG</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>MA</given-names></name><name><surname>Dela Cruz</surname><given-names>CS</given-names></name><name><surname>Palm</surname><given-names>NW</given-names></name><name><surname>Jackson</surname><given-names>R</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity</article-title><source>Nature</source><volume>573</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1485-8</pub-id><pub-id pub-id-type="pmid">31435009</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinman</surname><given-names>RM</given-names></name><name><surname>Hawiger</surname><given-names>D</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Tolerogenic dendritic cells</article-title><source>Annual Review of Immunology</source><volume>21</volume><fpage>685</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141040</pub-id><pub-id pub-id-type="pmid">12615891</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinman</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Decisions about dendritic cells: past, present, and future</article-title><source>Annual Review of Immunology</source><volume>30</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-100311-102839</pub-id><pub-id pub-id-type="pmid">22136168</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockinger</surname><given-names>B</given-names></name><name><surname>Veldhoen</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Th17 T cells: linking innate and adaptive immunity</article-title><source>Seminars in Immunology</source><volume>19</volume><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2007.10.008</pub-id><pub-id pub-id-type="pmid">18023589</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaeth</surname><given-names>M</given-names></name><name><surname>Schliesser</surname><given-names>U</given-names></name><name><surname>Müller</surname><given-names>G</given-names></name><name><surname>Reissig</surname><given-names>S</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name><name><surname>Tuettenberg</surname><given-names>A</given-names></name><name><surname>Jonuleit</surname><given-names>H</given-names></name><name><surname>Waisman</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>MR</given-names></name><name><surname>Serfling</surname><given-names>E</given-names></name><name><surname>Sawitzki</surname><given-names>BS</given-names></name><name><surname>Berberich-Siebelt</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from foxp3+ regulatory T cells</article-title><source>PNAS</source><volume>109</volume><fpage>16258</fpage><lpage>16263</lpage><pub-id pub-id-type="doi">10.1073/pnas.1203870109</pub-id><pub-id pub-id-type="pmid">22991461</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2012">2012a</year><article-title>Metabolic checkpoints in activated T cells</article-title><source>Nature Immunology</source><volume>13</volume><fpage>907</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1038/ni.2386</pub-id><pub-id pub-id-type="pmid">22990888</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2012">2012b</year><article-title>Metabolic reprogramming and metabolic dependency in T cells</article-title><source>Immunological Reviews</source><volume>249</volume><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2012.01155.x</pub-id><pub-id pub-id-type="pmid">22889212</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The calcineurin-NFAT axis controls allograft immunity in myeloid-derived suppressor cells through reprogramming T cell differentiation</article-title><source>Molecular and Cellular Biology</source><volume>35</volume><fpage>598</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1128/MCB.01251-14</pub-id><pub-id pub-id-type="pmid">25452304</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Histone deacetylase SIRT1 negatively regulates the differentiation of interleukin-9-producing CD4(+) T cells</article-title><source>Immunity</source><volume>44</volume><fpage>1337</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.009</pub-id><pub-id pub-id-type="pmid">27317260</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Qian</surname><given-names>N</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Hair shaft miniaturization causes stem cell depletion through mechanosensory signals mediated by a piezo1-calcium-tnf-α axis</article-title><source>Cell Stem Cell</source><volume>29</volume><fpage>70</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2021.09.009</pub-id><pub-id pub-id-type="pmid">34624205</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>XO</given-names></name><name><surname>Nurieva</surname><given-names>R</given-names></name><name><surname>Martinez</surname><given-names>GJ</given-names></name><name><surname>Kang</surname><given-names>HS</given-names></name><name><surname>Chung</surname><given-names>Y</given-names></name><name><surname>Pappu</surname><given-names>BP</given-names></name><name><surname>Shah</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>SH</given-names></name><name><surname>Schluns</surname><given-names>KS</given-names></name><name><surname>Watowich</surname><given-names>SS</given-names></name><name><surname>Feng</surname><given-names>X-H</given-names></name><name><surname>Jetten</surname><given-names>AM</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Molecular antagonism and plasticity of regulatory and inflammatory T cell programs</article-title><source>Immunity</source><volume>29</volume><fpage>44</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.05.007</pub-id><pub-id pub-id-type="pmid">18585065</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Zha</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Lei</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha</article-title><source>Science</source><volume>324</volume><fpage>261</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1126/science.1170944</pub-id><pub-id pub-id-type="pmid">19359588</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Lopes</surname><given-names>JE</given-names></name><name><surname>Chong</surname><given-names>MMW</given-names></name><name><surname>Ivanov</surname><given-names>II</given-names></name><name><surname>Min</surname><given-names>R</given-names></name><name><surname>Victora</surname><given-names>GD</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Rubtsov</surname><given-names>YP</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name><name><surname>Ziegler</surname><given-names>SF</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TGF-beta-induced foxp3 inhibits T(H)17 cell differentiation by antagonizing rorgammat function</article-title><source>Nature</source><volume>453</volume><fpage>236</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1038/nature06878</pub-id><pub-id pub-id-type="pmid">18368049</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Paul</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Heterogeneity and plasticity of T helper cells</article-title><source>Cell Research</source><volume>20</volume><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/cr.2009.138</pub-id><pub-id pub-id-type="pmid">20010916</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Yamane</surname><given-names>H</given-names></name><name><surname>Paul</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Differentiation of effector CD4 T cell populations (*)</article-title><source>Annual Review of Immunology</source><volume>28</volume><fpage>445</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-030409-101212</pub-id><pub-id pub-id-type="pmid">20192806</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79957.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Kellie N</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>The Johns Hopkins University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.05.17.492270" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.17.492270"/></front-stub><body><p>In the present study, the authors use mouse cancer models to study the role of Piezo1 on DC-mediated priming of CD4<sup>+</sup> T cells. They show that Piezo1 knockout results in faster tumor progression and accumulation of more regulatory T cells, and that Smad3 and STAT4 are involved in DC-mediated differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cells. Overall this represents a mechanistic advance in our understanding of DC biology as it relates to cancer. This also has the potential to extend beyond cancer to better our understanding of DC-mediated T cell differentiation.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79957.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Smith</surname><given-names>Kellie N</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>The Johns Hopkins University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Smith</surname><given-names>Kellie N</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>The Johns Hopkins University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Storkus</surname><given-names>Walter</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>University of Pittsburgh School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.17.492270">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.05.17.492270v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Dendritic cell Piezo1 integrating mechanical stiffness and inflammatory signals directs the differentiation of T<sub>H</sub>1 and T<sub>reg</sub> cells in cancer&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Kellie N Smith as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Walter Storkus (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Exploring the expression of Piezo1 in human DC.</p><p>2) Changes to the narration, text, and length as recommended by the reviewers.</p><p>3) TGFb Ab and recombinant IL-12 rescue experiments.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. Overall, the study is too long and could benefit from a focus on the key novel findings. While this reviewer appreciates the several instances of orthogonal validation of the salient findings, less text &quot;real estate&quot; could be devoted to these confirmatory experiments.</p><p>2. Most of Fig. 3 could be removed or shortened.</p><p>3. Line 135: &quot;Thus, we conclude that DC-specific Piezo1 deficiency alters the differentiation of Th1 and Treg cells during age-related T cell responses.&quot; -The data do not show that the immunological effects are age-related, but rather show that the clinical manifestation is age-related.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The key Th1, Th2, and Th17 transcription factors should be included in the work.</p><p>In Figure 1, the authors showed enhanced tumor growth in Piezo1ΔDC mice compared to WT. They showed increased FoxP3+ Tregs and decreased IFNγ+ Th1 cells in tumors of Piezo1ΔDC mice. They suggested these CD4 T cell changes probably promoted the tumor growth. This is not conclusive at all. How about CD8 T cell? Are there any changes in CD8 T cell number and function between Piezo1ΔDC and WT mice?</p><p>In Figure 4, the authors claimed that DC Piezo1 regulated T cell differentiation through IL-12 and TGFb1 signaling in vitro. Can they confirm these findings in vivo? Can anti-TGFb antibody or recombinant IL-12 protein reverse tumor phenotypes of Piezo1ΔDC mice?</p><p>The authors mentioned that there are no differences in the phenotype (CD80, CD86, MHC II) of DCs between WT and Piezo1ΔDC mice. How about key cytokine production or phagocytic activity/Ag presentation capacity?</p><p>All of the experiments were performed in mouse cells and one single mouse tumor model (MC38). Do human dendritic cells express Piezo1? Could they show comparable results in another tumor model?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Technical concerns and specific changes in text/figures were suggested to the authors for improvement.</p><p>1) IL-12p40 was analyzed for Type-1 DC output, yet IL-12p40 can homodimerize with itself or heterodimerize with IL-12p35 or IL-23p19 to produce either IL-12p70 or IL-23, respectively. The authors should indicate if Piezo1-activated DC produce more IL-12p40 homodimers, IL-12p70, and/or IL-23 to further refine their reported data set.</p><p>2) To better balance the T cell output cytokines associated with functional polarization, it is recommended that the authors include a Treg-kine, such as IL-10. Th1 (IFNG), Th2 (IL-4), and Th17 (IL-17) were used in the report, but Treg are only marked by Foxp3 expression.</p><p>3) Within the context of DC phenotype profiling, the authors suggest that Piezo1 status does not modulate DC expression of CD54, CD80 or CD86, suggesting a lack of impact on DC maturation. The authors should report whether Piezo1(deltaDC) expresses lower levels of CCR7, higher levels of checkpoint molecules (i.e. PD-L1, PD-L2, etc.), and higher rates of apoptosis vs. wild-type DC which could also factor into whether Type-1 vs. Treg responses are stimulated by these APCs.</p><p>4) Does intratumoral delivery of Yoda1 promote MC38 tumor growth control in wild-type mice in association with Type 1 &gt;&gt; Treg TIL phenotype?</p><p>5) At the end of the Discussion, the authors state &quot;(these findings have)...implications for targeting DCs as an approach to the treatment of cancer&quot;. This should be a bit more forward of a statement. How do the authors envision these data informing future clinical trial design in the cancer setting? (application of Piezo1 agonists such as Yoda1, etc.). Given a range of alternate DC agonists that would be envisioned to potentiate Type-1 T cell responses (i.e. TLR agonists, STING agonists, among others), please invest a bit more effort in developing a translational paradigm here that would speak to the preferred use of Piezo1-targeted strategies.</p><p>6) In Fig. 1, the faster growth rate of MC38 tumors in Piezo1(deltaDC) mice is presumed to be due to more Treg and fewer Type-1 (CD8+ T cells), but data are merely correlative. Can the authors speak to whether depletion of Treg in the KO mice results in control tumor growth (as observed in wild-type mice)?</p><p>7) For the studies involving T cell coculture with (2 kPa vs. 50 kPa) hydrogel-conditioned DCs + Antigen, are the DCs isolated first and then cocultured with T cells, or are T cells merely added to the DC-conditioned cultures? If the latter, the authors should comment on intrinsic stiffness-related aspects in the T cell responders as it relates to study outcomes.</p><p>8) Fig. 4A right (MFI) panels require labels for TGFB1 and IL-12.</p><p>9) The title for Supplemental Figure 6 is incorrect as it reports comparative expression of TGFBR1, TGFBR3, and IL-12RB1 on DC. The title for Supplemental Figure 7 is incorrect as it merely shows the impact of shRNA knockdown on target gene expression in DC. Please correct.</p><p>10) Similarly, the title for Supplemental Figures 8, 9, and 11/12/14 appear incorrect since TGFB1/IL-12 are not readouts in the data presented in Fig. S8, SIRT1/HIF1A are not interrogated in Fig. S9 and IL-12 is not an outcome index in Fig. S11/12/14. Please correct.</p><p>11) In the cartoon supplied in Supplemental Figure 15, the bottom &quot;Promoting cancer growth&quot; should be deleted and replaced by a red legend for &quot;Tumor progression&quot; below the Treg column, and a yellow legend for Tumor Growth Control&quot; under the Th1 column for reader clarity.</p><p>12) Although generally well-written, the report is very long and should be consolidated as much as is possible.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79957.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential Revisions (for the authors):</p><p>1) Exploring the expression of Piezo1 in human DC.</p></disp-quote><p>Thanks for the editor and reviewer’s suggestions. We have included the new data in Figure 7C-H in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>2) Changes to the narration, text, and length as recommended by the reviewers.</p></disp-quote><p>Thanks for the editor and reviewer’s suggestions. Following the reviewer’s comments, we have revised the manuscript now.</p><disp-quote content-type="editor-comment"><p>3) TGFb Ab and recombinant IL-12 rescue experiments.</p></disp-quote><p>Thanks for the editor and reviewer’s comments. We have included the new data in Figure 7A-B to show that changing IL-12 and TGFβ signaling can significantly alter T cell differentiation in the tumor environment in anti-tumor immunity in revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. Overall, the study is too long and could benefit from a focus on the key novel findings. While this reviewer appreciates the several instances of orthogonal validation of the salient findings, less text &quot;real estate&quot; could be devoted to these confirmatory experiments.</p></disp-quote><p>Thanks for the reviewer’s suggestions. Following the reviewer’s comments, we have revised and shortened the text.</p><disp-quote content-type="editor-comment"><p>2. Most of Fig. 3 could be removed or shortened.</p></disp-quote><p>Thanks. Following the reviewer’s comments, we have removed the original Fig.3 to Figure 3-figure supplement 1-2 now.</p><disp-quote content-type="editor-comment"><p>3. Line 135: &quot;Thus, we conclude that DC-specific Piezo1 deficiency alters the differentiation of Th1 and Treg cells during age-related T cell responses.&quot; -The data do not show that the immunological effects are age-related, but rather show that the clinical manifestation is age-related.</p></disp-quote><p>Thanks. Following the reviewer’s suggestions, we have revised the description in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The key Th1, Th2, and Th17 transcription factors should be included in the work.</p></disp-quote><p>Thanks. Following the reviewer’s suggestions, we have included the new data in Figure 1—figure supplement 4C, Figure 3—figure supplement 2A, and also added the descriptions accordingly in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>In Figure 1, the authors showed enhanced tumor growth in Piezo1ΔDC mice compared to WT. They showed increased FoxP3+ Tregs and decreased IFNγ+ Th1 cells in tumors of Piezo1ΔDC mice. They suggested these CD4 T cell changes probably promoted the tumor growth. This is not conclusive at all. How about CD8 T cell? Are there any changes in CD8 T cell number and function between Piezo1ΔDC and WT mice?</p></disp-quote><p>Thanks for the reviewer’s suggestions and comments. Following the reviewer’s suggestions, we revised the text and have also included the new data in Figure 1—figure supplement 4A-B to show the CD8<sup>+</sup>T cell number and IFNγ production in tumor in WT and <italic>Piezo1</italic><sup>-/-</sup> mice and added the new descriptions in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>In Figure 4, the authors claimed that DC Piezo1 regulated T cell differentiation through IL-12 and TGFb1 signaling in vitro. Can they confirm these findings in vivo? Can anti-TGFb antibody or recombinant IL-12 protein reverse tumor phenotypes of Piezo1ΔDC mice?</p></disp-quote><p>Thanks for the reviewer’s comments. We have included the new data in Figure 7A-B to show that changing IL-12 and TGFβ signaling can significantly reverse the tumor growth and alter T cell differentiation in the tumor environment in revised manuscript.</p><disp-quote content-type="editor-comment"><p>The authors mentioned that there are no differences in the phenotype (CD80, CD86, MHC II) of DCs between WT and Piezo1ΔDC mice. How about key cytokine production or phagocytic activity/Ag presentation capacity?</p></disp-quote><p>Thanks for the reviewer’s suggestions. We have included the new data in Figure 3—figure supplement 4A-C, Figure 3—figure supplement 3D and added the descriptions about the Figure 2A and Figure 2D in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>All of the experiments were performed in mouse cells and one single mouse tumor model (MC38). Do human dendritic cells express Piezo1? Could they show comparable results in another tumor model?</p></disp-quote><p>Thanks for the reviewer’s suggestions. We have included the new data in Figure 1—figure supplement 5A-B (B16.F10 melanoma tumor) and Figure 7C-H (human DCs) in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Technical concerns and specific changes in text/figures were suggested to the authors for improvement.</p><p>1) IL-12p40 was analyzed for Type-1 DC output, yet IL-12p40 can homodimerize with itself or heterodimerize with IL-12p35 or IL-23p19 to produce either IL-12p70 or IL-23, respectively. The authors should indicate if Piezo1-activated DC produce more IL-12p40 homodimers, IL-12p70, and/or IL-23 to further refine their reported data set.</p></disp-quote><p>Thanks for the reviewer’s suggestions. We have included the new data in Figure 3-figure supplement 4B-C in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>2) To better balance the T cell output cytokines associated with functional polarization, it is recommended that the authors include a Treg-kine, such as IL-10. Th1 (IFNG), Th2 (IL-4), and Th17 (IL-17) were used in the report, but Treg are only marked by Foxp3 expression.</p></disp-quote><p>Thanks for the reviewer’s suggestions. We have included the new data in Figure 1-figure supplement 4C and Figure 3-figure supplement 2A in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>3) Within the context of DC phenotype profiling, the authors suggest that Piezo1 status does not modulate DC expression of CD54, CD80 or CD86, suggesting a lack of impact on DC maturation. The authors should report whether Piezo1(deltaDC) expresses lower levels of CCR7, higher levels of checkpoint molecules (i.e. PD-L1, PD-L2, etc.), and higher rates of apoptosis vs. wild-type DC which could also factor into whether Type-1 vs. Treg responses are stimulated by these APCs.</p></disp-quote><p>Thanks for the reviewer’s suggestions. We have included the new data in Figure 3-figure supplement 3C and 3A in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>4) Does intratumoral delivery of Yoda1 promote MC38 tumor growth control in wild-type mice in association with Type 1 &gt;&gt; Treg TIL phenotype?</p></disp-quote><p>Thanks for the reviewer’s suggestions. We have added discussion in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>5) At the end of the Discussion, the authors state &quot;(these findings have)...implications for targeting DCs as an approach to the treatment of cancer&quot;. This should be a bit more forward of a statement. How do the authors envision these data informing future clinical trial design in the cancer setting? (application of Piezo1 agonists such as Yoda1, etc.). Given a range of alternate DC agonists that would be envisioned to potentiate Type-1 T cell responses (i.e. TLR agonists, STING agonists, among others), please invest a bit more effort in developing a translational paradigm here that would speak to the preferred use of Piezo1-targeted strategies.</p></disp-quote><p>Thanks for the reviewer’s suggestions. Following the reviewer’s comments, we have revised the descriptions in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>6) In Fig. 1, the faster growth rate of MC38 tumors in Piezo1(deltaDC) mice is presumed to be due to more Treg and fewer Type-1 (CD8+ T cells), but data are merely correlative. Can the authors speak to whether depletion of Treg in the KO mice results in control tumor growth (as observed in wild-type mice)?</p></disp-quote><p>Thanks for the reviewer’s suggestions. Following the reviewer’s comments, we have included the data in new Fig.7A-B and added the descriptions to show the T cell differentiation is critical for the tumor growth control induced by DC Piezo1 deficient.</p><disp-quote content-type="editor-comment"><p>7) For the studies involving T cell coculture with (2 kPa vs. 50 kPa) hydrogel-conditioned DCs + Antigen, are the DCs isolated first and then cocultured with T cells, or are T cells merely added to the DC-conditioned cultures? If the latter, the authors should comment on intrinsic stiffness-related aspects in the T cell responders as it relates to study outcomes.</p></disp-quote><p>Thanks for the reviewer’s suggestions. We isolated DCs first and then cocultured with T cells. Following the reviewer’s suggestions, we have revised the figure legend in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>8) Fig. 4A right (MFI) panels require labels for TGFB1 and IL-12.</p><p>9) The title for Supplemental Figure 6 is incorrect as it reports comparative expression of TGFBR1, TGFBR3, and IL-12RB1 on DC. The title for Supplemental Figure 7 is incorrect as it merely shows the impact of shRNA knockdown on target gene expression in DC. Please correct.</p><p>10) Similarly, the title for Supplemental Figures 8, 9, and 11/12/14 appear incorrect since TGFB1/IL-12 are not readouts in the data presented in Fig. S8, SIRT1/HIF1A are not interrogated in Fig. S9 and IL-12 is not an outcome index in Fig. S11/12/14. Please correct.</p></disp-quote><p>Thanks for the reviewer’s criticisms and comments. We have corrected them in the figure legends.</p><disp-quote content-type="editor-comment"><p>11) In the cartoon supplied in Supplemental Figure 15, the bottom &quot;Promoting cancer growth&quot; should be deleted and replaced by a red legend for &quot;Tumor progression&quot; below the Treg column, and a yellow legend for Tumor Growth Control&quot; under the Th1 column for reader clarity.</p></disp-quote><p>Thanks for the reviewer’s suggestions. Following the reviewer’s suggestions, we have revised the cartoon in the new Figure 7-figure supplement 1.</p><disp-quote content-type="editor-comment"><p>12) Although generally well-written, the report is very long and should be consolidated as much as is possible.</p></disp-quote><p>Thanks for the reviewer’s suggestions. Following the reviewer’s suggestions, we consolidated some contents and shortened the length of the article now.</p></body></sub-article></article>